A

Abdomen
abscess in, in critically ill, Aug., 551–554
cramping in VIPoma, June, 369
neuroblastoma
chemotherapy, photograph after, Sept., 609
physical findings, Sept., 599–600
pain in somatostatinoma, June, 367
upper, spindle cell sarcoma in, multiple organ transplant for, Apr., 223
wall tenderness after gallstone lithotripsy, Nov., 753
Abdominoperineal resection: for rectal cancer, May, 273
Abdominosacral resection: for rectal cancer, May, 265–266
ABO
-compatible donors, liver transplantation in, Mar., 123–126
-incompatible donors, liver transplantation in, Mar., 126–129
Abscess
intraabdominal, in critically ill, Aug., 551–554
liver, CT-guided percutaneous drainage of, Aug., 553
Achlorhydria
in somatostatinoma, June, 366
in VIPoma, June, 360
Acinic cell carcinoma: of parotid gland, Dec., 798
Acquired immunodeficiency syndrome (see AIDS)
Acyclovir: for Epstein-Barr viral disorders after liver transplant, Apr., 192
Adenocarcinoma
parotid gland, Dec., 797
clinical presentation, Dec., 807
prostate
(*See also* Cancer, prostate)
histologic patterns, *July*, 400–401
rectal (*see* Rectal cancer)
submaxillary gland, locally advanced high-grade, Dec., 810
Adenoid cystic carcinoma
parotid gland, Dec., 797–798
salivary gland, Dec., 812
metastatic, treatment, Dec., 833
Adenoma: monomorphic, of parotid gland, Dec., 795
Adenomatosis: liver transplantation for, Apr., 217
Adenoviral hepatitis: after liver transplantation, Apr., 193–194
Adrenal insufficiency: in critically ill, Aug., 559
Adrenocorticotropinomas: of pancreas, June, 369
Adriamycin (*see* Doxorubicin)
Age
glucagonoma and, June, 347
insulinoma and, June, 336
liver transplantation and, Apr., 209
as predictor of congestive heart failure, Aug., 519
prostate cancer and, July, 396
somatostatinoma and, June, 364
Zollinger-Ellison syndrome and, June, 317
AIDS
liver transplantation and, Apr., 213
parotid gland in, Dec., 789
Airway
pressure
curves for spontaneous and positive pressure ventilation, Aug., 478
during pressure support, Aug., 512
resistance, effect of endotracheal tube size on, Aug., 513
Alcohol: fetal alcohol syndrome and neuroblastoma, Sept., 597

A

Abdomen
abscess in, in critically ill, Aug., 551–554
cramping in VIPoma, June, 369
neuroblastoma
chemotherapy, photograph after, Sept., 609
physical findings, Sept., 599–600
pain in somatostatinoma, June, 367
upper, spindle cell sarcoma in, multiple organ transplant for, Apr., 223
wall tenderness after gallstone lithotripsy, Nov., 753
Abdominoperineal resection: for rectal cancer, May, 273
Abdominosacral resection: for rectal cancer, May, 265–266
ABO
-compatible donors, liver transplantation in, Mar., 123–126
-incompatible donors, liver transplantation in, Mar., 126–129
Abscess
intraabdominal, in critically ill, Aug., 551–554
liver, CT-guided percutaneous drainage of, Aug., 553
Achlorhydria
in somatostatinoma, June, 366
in VIPoma, June, 360
Acinic cell carcinoma: of parotid gland, Dec., 798
Acquired immunodeficiency syndrome (see AIDS)
Acyclovir: for Epstein-Barr viral disorders after liver transplant, Apr., 192
Adenocarcinoma
parotid gland, Dec., 797
clinical presentation, Dec., 807
prostate
(*See also* Cancer, prostate)
histologic patterns, *July*, 400–401
rectal (*see* Rectal cancer)
submaxillary gland, locally advanced high-grade, Dec., 810
Adenoid cystic carcinoma
parotid gland, Dec., 797–798
salivary gland, Dec., 812
metastatic, treatment, Dec., 833
Adenoma: monomorphic, of parotid gland, Dec., 795
Adenomatosis: liver transplantation for, Apr., 217
Adenoviral hepatitis: after liver transplantation, Apr., 193–194
Adrenal insufficiency: in critically ill, Aug., 559
Adrenocorticotropinomas: of pancreas, June, 369
Adriamycin (*see* Doxorubicin)
Age
glucagonoma and, June, 347
insulinoma and, June, 336
liver transplantation and, Apr., 209
as predictor of congestive heart failure, Aug., 519
prostate cancer and, July, 396
somatostatinoma and, June, 364
Zollinger-Ellison syndrome and, June, 317
AIDS
liver transplantation and, Apr., 213
parotid gland in, Dec., 789
Airway
pressure
curves for spontaneous and positive pressure ventilation, Aug., 478
during pressure support, Aug., 512
resistance, effect of endotracheal tube size on, Aug., 513
Alcohol: fetal alcohol syndrome and neuroblastoma, Sept., 597

Alfentanil: for gallstone lithotripsy, Nov., 747
Amine precursor uptake and decarboxylation, June, 309-311
Ampulla of Vater: somatostatinoma in, June, 364
Amyloid A protein: and liver transplant rejection, Mar., 157
Analgesia for lithotripsy
  of bile duct stones, Nov., 756
  of gallstones, Nov., 747
Anasarca: in critically ill, Aug., 528
Anastomosis
  for rectal cancer (*see* Rectal cancer, anastomosis for)
  strictures (*see* Strictures, anastomotic)
Anatomy: prostate, zonal, July, 398–399
Androgen
  administration causing prostate cancer (in animals), July, 398
  withdrawal in prostate cancer, July, 451
Anemia: in glucagonoma, June, 351
Anesthesia
  for lithotripsy of bile duct stones, Nov., 756
  for vascular access surgery for hemodialysis, Jan., 18
Aneurysm: complicating vascular access for hemodialysis, Jan., 33–34
Angiography
  of AV fistula for hemodialysis, in-use, Jan., 37
  in glucagonoma, June, 352–354
  in insulinoma, June, 342
  in VIPoma, June, 361, 362
  in Zollinger-Ellison syndrome, June, 324, 326–327
Angioplasty: percutaneous, for salvage of vascular access for hemodialysis, Jan., 38–39
Anomalies, donor arterial, in liver transplantation, Feb., 64
  reconstruction of, Feb., 65, 66
Antacids: in prevention of stress gastritis, Aug., 555
Antecubital fistula: for hemodialysis, Jan., 23
Antibiotics: prophylactic, in liver transplant recipients, Apr., 187
Antibody(ies)
  blocking, in neuroblastoma, Sept., 591
  lymphotoxic, in liver transplant, Mar., 125
  monoclonal
    antiendotoxin, in liver transplantation, Mar., 136
    in neuroblastoma diagnosis, Sept., 593
Anticholinergics: in Zollinger-Ellison syndrome, June, 331
Anticoagulation: during extracorporeal life support, Oct., 647–649
Antidiuretic hormone: effects on renal function, Aug., 525
Antiendotoxin monoclonal antibodies: in liver transplantation, Mar., 136
Antigens
  MHC, in liver transplant rejection, Mar., 153–154
  prostate specific, in prostate cancer
    for diagnosis, July, 406–408, 409, 423–433
    postoperative levels, July, 409
    for staging, July, 421–422
Anti-inflammatory agents: nonsteroidal, effect on gallstone recurrence, Nov., 760
Antilymphocyte globulin: in liver transplantation, Mar., 138, 139
Antithrombin deficiency: and thrombosis in liver transplantation, in children, Feb., 99
Aortic infusion alone: for core cooling of liver, Feb., 62–63
Apache II, Aug., 557
Aplasia: bone marrow, and hepatitis after liver transplant, Apr., 198

Arteries
access, implantable system for, Jan., 13–15
Basel experience with, Jan., 15
anomalies, donor, in liver transplantation, Feb., 64
reconstruction of, Feb., 65, 66
hepatic (*see* Hepatic, artery)
mesenteric (*see* Mesenteric artery)
pulmonary artery catheter (*see* Catheter, pulmonary artery)
pulse pressure during venoarterial cardiopulmonary bypass, Oct., 644
ulnar, demonstration of supplementation to fistula flow by, Jan., 19
venoarterial extracorporeal circulation (*see* Extracorporeal life support, venoarterial)
Arteriovenous
extracorporeal circulation, Oct., 634–636
fistula (*see under* Vascular access for hemodialysis, maintenance)
Arteritis: after FK 506 in liver transplantation (in dog), Mar., 144
Artificial
lungs for extracorporeal life support (*see* Extracorporeal life support, membrane lungs for)
organs for extracorporeal life support, Oct., 686–688
Aspiration
biopsy, fine-needle, of salivary gland tumors, Dec., 819–820
cytology, fine-needle, in prostate cancer, July, 403
Aspirin: effect on gallstone recurrence, Nov., 760
ATP: and liver allograft failure, Feb., 102
^{198}Au implantation radiotherapy: in prostate cancer, July, 447–448
Autoimmune hepatitis: after liver transplant, Apr., 212

B

Bacille Calmette-Guérin: in rectal cancer, May, 283
Bacteremia: in critically ill, Aug., 550–551
Bacterial
infections after liver transplantation, Apr., 187–188
sialadenitis, acute, Dec., 787
translocation
hypothesis, outline of, Aug., 548
in liver transplantation, Apr., 187
nutrition and, total parenteral, Aug., 548
B-cell lymphomas: after liver transplantation, Apr., 192
Beta$_2$-microglobulin: and liver transplant rejection, Mar., 157
Bicellular theory: of histogenesis of salivary gland tumors, Dec., 780
Bile
changes and liver transplant rejection, Mar., 157
cholesterol saturation in, Nov., 719
effects of oral dissolution agents on, Nov., 723
duct
dilation, ultrasound of, Aug., 545
stones (*see* Stones, bile duct)
syndrome, vanishing, after liver transplant, Apr., 190
Biliary
cirrhosis (*see* Cirrhosis, biliary)
colic after gallstone lithotripsy, Nov., 748, 750, 751, 753
complications after liver transplant, pathologist's view, Apr., 199–201
lithotripsy, Nov., 717–772
reconstruction in liver transplantation (*see* Transplantation, liver, biliary reconstruction in)
Bilirubin: serum, and liver transplant rejection, Mar., 157

Biloma formation: in dearterialized liver, Feb., 98
Biology of neuroblastoma, Sept., 580–583
  cellular, Sept., 591
Biopsy
  fine-needle aspiration, of salivary gland tumors, Dec., 819–820
  liver
    needle *(see below)*
    in neuroblastoma, Sept., 608
    reperfusion, hepatocellular necrosis in, Feb., 105
    results before and after FK506 in liver transplantation, Mar., 146
  liver, needle, after transplantation for adenoviral hepatitis, Apr., 194
  in biliary complications, Apr., 199–200
    in cytomegalovirus infection, Apr., 189
    for Epstein-Barr virus disorders, Apr., 192–193
    in hepatic artery thrombosis, Feb., 97
  prostate, for cancer staging, July, 418–419
  specimens, lymphocytes from (*see* Lymphocytes, from biopsy specimens)
Blacks: liver transplantation in, Apr., 230
Blood
  activation in extracorporeal life support, Oct., 646–649
  cells, white, effect of extracorporeal life support on, Oct., 649
  flow
    cerebral, related to carbon dioxide tension, Aug., 477
    reduction, hepatic, causing liver graft failure, Feb., 99
    total, during venoarterial cardiopulmonary bypass, Oct., 644
  gas
    analysis in critically ill, Aug., 482–483
    venous, mixed, measurements in sepsis, Aug., 489
  oxygen measurement in, Oct., 637
  supply of nephron, Aug., 526
  transfusions in liver transplantation, Mar., 126
Body surface area: nomogram relating height and weight to, Aug., 498
Bone
  marrow (*see* Marrow)
  radiographs for prostate cancer staging, July, 423
  scans in prostate cancer staging, July, 422
Bovine carotid heterograft: for hemodialysis, Jan., 27–28
Bowel: small, somatostatinoma in, June, 364
Brachiobasilic fistula: for hemodialysis, Jan., 23–24, 25
Brachiocephalic fistula: for hemodialysis, Jan., 23
Breast carcinoma: metastatic to parotid gland, Dec., 808
Breathing: work of, effect of endotracheal tube size on, Aug., 513
Brescia-Cimino fistula for hemodialysis, Jan., 20
  patency rate, Jan., 31
Budd-Chiari syndrome: after liver transplant, Apr., 212
Bypass, cardiopulmonary (*see* Extracorporeal life support)

C

Calcium
  infusion
    in insulinoma diagnosis, June, 341
    in Zollinger-Ellison syndrome diagnosis, June, 322
  role in pathogenesis of cholesterol gallstones, Nov., 720
Cancer
  chemotherapy, vascular access for, Jan., 8

Cancer *(cont.)*
in children, incidence of, Sept., 581
colorectal
(*See also* Rectal cancer)
individuals at increased risk for, May, 248
liver
in donor, causing allograft failure, Feb., 95
transplantation for, Apr., 205–207
transplantation for, survival rates, Apr., 208
prostate, July, 395–461
anatomy of prostate and, zonal, July, 398–399
architecture, July, 400–402
cytology, fine-needle aspiration, July, 403
diagnosis, July, 406–411
diagnosis, digital rectal examination in, July, 406, 432, 433
diagnosis, early, July, 432–433
diagnosis, prostate specific antigen in, July, 406–408, 409, 432–433
diagnosis, ultrasound in, transrectal, July, 408, 410–411, 423–433
dissemination, hematogenous, July, 404–406
dissemination patterns, July, 403–406
epidemiology, July, 395–397
estrogen-induced changes in, July, 402
etiology, July, 397–398
etiology, hormonal, July, 398
etiology, infectious, July, 398
extension, local, July, 404
future prospects, July, 453–454
genetic predisposition, July, 397
grading, July, 402
immunohistochemistry, July, 400
lymph node evaluation in (*see* Lymph node, evaluation in prostate cancer)
lymphadenectomy in, staging pelvic, July, 424–426
lymphatic spread, July, 404
management, overview of, July, 433–437
metastatic, chemotherapy in, July, 452–453
metastatic, management, July, 449–453
metastatic, mixed osteoblastic and osteolytic metastases in, July, 405
natural history, July, 427–431
non-acinar, July, 403
pathology, July, 399–403
prostatectomy for (*see* Prostatectomy, radical, for prostate cancer)
radiotherapy in (*see* Radiotherapy, in prostate cancer)
stage(s), natural history of, July, 429
stage TA1, management, overview of, July, 436–437
stage TA1, natural history, July, 429–430
stage TA1, repeat transurethral resection for, July, 418
stage TA2, natural history, July, 430
stage TB1, natural history, July, 430
stage TB2, natural history, July, 431
stage TC, natural history, July, 431
stage TD1, natural history, July, 431
stage TD2, hormonally refractory, natural history, July, 431
stage TD2, natural history, July, 431
staging, July, 411–423
staging, biopsies for, diagnostic, July, 418–419
staging, bone scan in, July, 422
staging, CT for, July, 417
staging, cystoscopy for, July, 419
staging, digital rectal examination for, July, 416–417
staging, errors, July, 427

staging, MRI for, July, 417
staging, phosphatases for, serum, July, 419–421
staging procedures, indications for, July, 426–427
staging, prostate specific antigen for, July, 421–422
staging, radiograph for, bone, July, 423
staging, radiograph for, chest, July, 418
staging system, OSCC, diagram for, July, 412–413
staging, ultrasound for, July, 417
staging, urogram for, excretory, July, 418
surgery for, exenterative, July, 444
rectal (*see* Rectal cancer)
salivary gland (*see* Salivary gland, tumors)
Cannulation: for extracorporeal life support, Oct., 660–661
Carbon dioxide
production, Oct., 638–639
removal
extracorporeal, Oct., 641–643
extracorporeal, evolution of concept of, Oct., 631–632
tension related to cerebral blood flow, Aug., 477
Carboplatinum: in neuroblastoma, Sept., 603–604
Carcinogens: chemical, in prostate cancer, July, 396
Carcinoma
adenocarcinoma (*see* Adenocarcinoma)
breast, metastatic to parotid gland, Dec., 808
hepatocellular, liver transplant for, Apr., 206
survival rates after, Apr., 207
parotid gland
acinic cell, Dec., 798
adenoid cystic, Dec., 797–798
anaplastic, Dec., 808
metastatic to cervical lymph nodes, Dec., 828, 829
mucoepidermoid, Dec., 795–796
squamous cell, Dec., 798
squamous cell, fungating metastatic, Dec., 809
undifferentiated, Dec., 798–799
salivary gland
adenoid cystic, Dec., 812
adenoid cystic, metastatic, treatment, Dec., 833
metastatic to cervical lymph nodes, Dec., 828, 830
neck dissection in, Dec., 827–830
survival curves, by histologic subtypes, Dec., 838
survival curves, by site of origin, Dec., 836
survival rates, by stage of disease and time of treatment, Dec., 836
skin, squamous cell, metastatic to parotid gland, Dec., 809
submandibular gland, metastatic to cervical lymph nodes, Dec., 828, 829
Cardiac
(*See also* Heart)
arrest, extracorporeal life support for, Oct., 685
index, determination of, Aug., 501
output measurement, thermodilution, Aug., 497
Cardiopulmonary bypass (*see* Extracorporeal life support)
Cardiovascular symptoms: in insulinoma, June, 339
Carotid heterograft: bovine, for hemodialysis, Jan., 27–28
Carpal tunnel syndrome: complicating vascular access for hemodialysis, Jan., 36
Catecholamine(s)
metabolism, schema of, Sept., 592
in neuroblastoma, Sept., 591–592
urinary excretion, normal, Sept., 592
Catheter
central venous, Jan., 8–10
complications, Jan., 9–10

Catheter *(cont.)*
complications, septic, Jan., 9–10
complications, thrombotic, Jan., 10
insertion technique, Jan., 8–9
for extracorporeal life support, Oct., 658–660
in newborn, chest x-rays of placement, Oct., 670
pulmonary artery
access for, Aug., 492
illustration of, Aug., 494
insertion, devices used for, Aug., 494
insertion, pressure tracings during, Aug., 494
insertion, Seldinger technique, Aug., 493
location of, diagram, Aug., 491
for thermodilution cardiac output measurement, Aug., 497
values obtained directly from, Aug., 492
Cavitation: and shock waves, Nov., 734–736
Cell(s)
acinic cell carcinoma of parotid gland, Dec., 798
B-cell lymphomas after liver transplantation, Apr., 192
blood, white, effect of extracorporeal life support on, Oct., 649
dendritic, in liver transplant rejection, Mar., 154–155
islet cell tumors of pancreas with syndrome related to hypercalcemia, June, 369
Kupffer, in liver transplantation, Mar., 125
spindle cell sarcoma, upper abdominal, multiple organ transplant for, Apr., 223
squamous cell parotid gland carcinoma, Dec., 798
fungating metastatic, Dec., 809
Cellular biology: of neuroblastoma, Sept., 591
Central venous
access for total parenteral nutrition, Jan., 8
catheter (*see* Catheter, central venous)
pressure in diagnosis of congestive heart failure, Aug., 528–529
Cerebral blood flow: related to carbon dioxide tension, Aug., 477
Cervical
lymph nodes (*see* Metastases, to lymph nodes, cervical)
neuroblastoma, Sept., 599
Chemical carcinogens: in prostate cancer, July, 396
Chemotherapy
cancer, vascular access for, Jan., 8
in dumbbell tumors, Sept., 613
in glucagonoma, June, 355
in neuroblastoma, Sept., 603–604
abdominal, photograph after, Sept., 609
multiagent, Sept., 605
responses, Sept., 604
single agent, Sept., 603
in prostate cancer, metastatic, July, 452–453
in rectal cancer, May, 282–283
combination, May, 282–283
with enhancement, May, 283
portal vein infusion, May, 289–291
radiotherapy combined with, May, 288–289
single agent, May, 282
in salivary gland tumors, Dec., 833
in somatostatinoma, June, 367
in VIPoma, June, 363
in Zollinger-Ellison syndrome, June, 334
Chenodeoxycholic acid for gallstones, Nov., 725
historical aspects, Nov., 721–722
mechanisms of action, Nov., 722–724
Chest x-ray (*see* Radiography, chest)
Children
extracorporeal life support centers for, in U.S., Oct., 692–693
malignancies in, incidence of, Sept., 581

neuroblastoma in (*see* Neuroblastoma)
newborn (*see* Newborn)
respiratory failure in (*see* Extracorporeal life support, for respiratory failure, in adults and older children)
salivary gland tumors in, Dec., 802–803
sympathetic nervous system in, schematic of, Sept., 586
transplantation in, heart, extracorporeal life support after, Oct., 683
transplantation in, liver, Apr., 209
with cyclosporine-steroids, survival rates, Apr., 206
with cyclosporine, survival rates, Mar., 138
Epstein-Barr virus-induced disorders after, Apr., 192
for fulminant hepatic failure, survival rates, Apr., 215
hepatitis after, adenoviral, Apr., 193–194
indications, Apr., 204
marrow aplasia and non-A, non-B hepatitis after, Apr., 198
partial, Feb., 92–93, 94
reduced size, Feb., 92
for situs inversus, Feb., 92–93
technical failure of, Feb., 96
thrombosis after, vascular, Feb., 98–99
transplantation in, multiple organ, Apr., 223
Cholecystectomy
efficacy of, Nov., 761–762
laparoscopic, Nov., 762
Cholesterol
gallstones, pathogenesis, Nov., 718–721
saturation in bile, Nov., 719
effects of oral dissolution agents on, Nov., 723
Chlorozotocin: in glucagonoma, June, 355
Cholangiolar proliferation: after liver transplantation, Feb., 107
Cholangiolitis: acute, after liver transplantation, Feb., 107
Cholangitis: sclerosing, after liver transplantation, Apr., 212
Cholecystokinin: as stimulant of pancreatic secretion, June, 370
Cholelithiasis (*see* Gallstones)
Cholestasis: hepatocanalicular, after liver transplantation, Feb., 107
Chromosome deletions: in prostate cancer, July, 397
Cimetidine: in Zollinger-Ellison syndrome, June, 330–331
Circulation, extracorporeal (*see* Extracorporeal life support)
Cirrhosis
biliary
after liver transplant, Apr., 212
primary, liver transplant for, survival after, Apr., 217
Laënnec's, liver transplant for, Apr., 209
prostate cancer and, July, 396
Cisplatinum: in neuroblastoma, Sept., 603, 604
Clark platinum electrode: for measuring partial pressure of oxygen, Aug., 483
Coagulation
control during extracorporeal life support, Oct., 646–649
during liver transplantation, Feb., 90–91
system failure in critically ill, Aug., 554
Colic: biliary, after gallstone lithotripsy, Nov., 748, 750, 751, 753
Colloid resuscitation: of hypovolemia, Aug., 532–534
Coloanal anastomosis: for rectal cancer, May, 262, 264, 265
Colonoscopy: in detection of rectal cancer, May, 249
Colorectal cancer (*see* Cancer, colorectal)
Coma: in insulinoma, June, 339
Computed tomography
of abscess, intraabdominal, Aug., 552

Computed tomography *(cont.)*
guidance of liver abscess drainage, Aug., 553
in insulinoma, June, 342, 343
/intravenous pyelography in neuroblastoma, Sept., 600–601
for lymph node evaluation in prostate cancer, July, 424
in neuroblastoma, Sept., 601–602
of parotid gland tumor, deep lobe, Dec., 817
in prostate cancer staging, July, 417
in rectal cancer staging, preoperative, May, 250
in salivary gland tumors, Dec., 815–819
sialogram of parotid gland tumor, Dec., 818
of Warthin's tumor, Dec., 816
in Zollinger-Ellison syndrome, June, 324, 325
Cooling
for liver procurement (*see* Transplantation, liver, cooling for)
for multiple organ procurement, Feb., 58–61
in situ, principle of, Feb., 61
Cost: of extracorporeal life support, Oct., 690
C-peptide suppression test: in insulinoma, June, 341
Cramping: abdominal, in VIPoma, June, 369
Creatinine clearance, Aug., 524–525
calculation of, Aug., 524
Cricothyroidotomy: in mechanically ventilated patients, Aug., 508–509
Critical care (*see* Surgical critical care)
Crossclamping: of portal triad in recipient hepatectomy, Feb., 80
Crystalloid resuscitation: of hypovolemia, Aug., 532–535
CT (*see* Computed tomography)
Cushing's syndrome: and Zollinger-Ellison syndrome, June, 321
Cutaneous (*see* Skin)
Cyclophosphamide
in dumbbell tumors, Sept., 613
in neuroblastoma, Sept., 603, 604
Cyclosporine
in liver transplantation, Mar., 139–141
effect on liver regeneration, Mar., 140–141
effect on lymphocyte clonal expansion, Mar., 143
effect on "rogue" clones, Mar., 144
limitations of, Mar., 139–140
with prednisone, survival rates after, Apr., 203
renal function after, Mar., 148–149
with steroids, survival rates after, Apr., 205
with steroids, survival rates after, in children, Apr., 206
survival rates, Mar., 138; Apr., 209
-resistant clones, development of, Mar., 144
Cystic
adenoid carcinoma (*see* Adenoid cystic carcinoma)
duct obstruction in liver transplantation, Feb., 88, 89
hygroma, liver transplantation for, Apr., 217
Cystoscopy: for prostate cancer staging, July, 419
Cytokines: activated by endotoxin, Mar., 131–132
Cytology: fine-needle aspiration, in prostate cancer, July, 403
Cytomegalovirus hepatitis: after liver transplantation, Apr., 189–190

D

Dacarbazine: in neuroblastoma, Sept., 603
Death (*see* Mortality)
Decannulation: for extracorporeal life support, Oct., 664–665

Decarboxylation: and amine precursor uptake, June, 309–311
Dendritic cells: in liver transplant rejection, Mar., 154–155
Dermatitis: necrotizing migratory, in glucagonoma, June, *Color Plates* at 344; 351
DES: in prostate cancer, July, 450
Diabetes mellitus
  glucagonoma-induced, June, 349–350
  somatostatinoma and, June, 366
Dialysis
  acute, Aug., 538–541
  hemodialysis (*see* Hemodialysis)
  peritoneal, acute, Aug., 538–541
Diarrhea
  in glucagonoma, June, 351
  in somatostatinoma, June, 366–367
  in VIPoma, June, 359–360
  in Zollinger-Ellison syndrome, June, 320–321
DiaTAB button device: for hemodialysis, Jan., 28
Diazoxide: in insulinoma, June, 346
Dietary factors: in prostate cancer, July, 396
Diethylstilbestrol: in prostate cancer, July, 450
Digital
  ischemic lesion due to steal syndrome, Jan., 36
  rectal examination (*see* Rectal examination, digital)
DNA content: of neuroblastoma, Sept., 591
Dopamine
  in neuroblastoma, Sept., 592
  in oliguria, Aug., 536
Doppler ultrasound
  of hepatic artery thrombosis after liver transplantation, Feb., 97
  of vascular access for hemodialysis, Jan., 38
Dornier lithotripter, Nov., 753
Doxorubicin
  in dumbbell tumors, Sept., 613
  in glucagonoma, June, 355
  in neuroblastoma, Sept., 603, 604
  in somatostatinoma, June, 367
Drainage: of liver abscess, CT-guided percutaneous, Aug., 553
Drug(s)
  anti-inflammatory, nonsteroidal, effect on gallstone recurrence, Nov., 760
  injury to allograft liver, Apr., 201
DTIC: in glucagonoma, June, 355
Dumbbell tumors: treatment of, Sept., 612–613
Duodenal somatostatinoma, June, 364–365

E

Echocardiography: during extracorporeal life support, Oct., 664
Eck fistula model: for study of cyclosporine in liver transplantation, Mar., 141
Economic factors: in liver transplantation, Apr., 229–230
Edema
  gallbladder, ultrasound of, Aug., 542
  pulmonary (*see* Pulmonary, edema)
Effector pathways: in liver transplant rejection, Mar., 155
Electrocoagulation: of rectal cancer, May, 268–271
Electrode: Clark platinum, for measuring partial pressure of oxygen, Aug., 483
Electrohydraulic lithotripsy: of bile duct stones, Nov., 755
Electrolyte solutions: oral, in VIPoma, June, 362
Electron microscopy (*see* Microscopy, electron)
Emaciation: lethal, after FK 506 in liver transplantation (in dog), Mar., 144
Embolism
  pulmonary, as complication of retropubic radical prostatectomy, July, 442
  thromboembolism in glucagonoma, June, 351

Embryologic development: of nervous system, stages of, Sept., 582
Embryology: of neuroblastoma, Sept., 580–584
Embryonal rhabdomyosarcoma: presenting as parotid mass, in children, Dec., 802
Endocrine
  neoplasia I, multiple (*see* MEN I)
  tumors of pancreas (*see* Pancreas, tumors, functional endocrine)
Endoluminal ultrasound: in rectal cancer staging, May, 251–252, 253
Endotoxemia: and liver transplantation, Mar., 129–136
Endotoxin
  levels in liver transplantation, Mar., 135
    (in dog), Mar., 134
  liver transplantation and, Mar., 130–136
  soluble mediators activated by, Mar., 131–132
Endotracheal tube
  resistance, Aug., 512–513
  size, effect on airway resistance and work of breathing, Aug., 513
Enolase: neuron-specific, in neuroblastoma, Sept., 592
Enteral feeding: in critically ill, Aug., 548–550
Enzyme increase: hepatic, and liver transplant rejection, Mar., 157
Eosinophilia: in liver transplant rejection, Mar., 157
Epithelioid hemangioendothelioma: liver transplant for, Apr., 206
Epstein-Barr virus disorders: after liver transplantation, Apr., 191–193
Estrogen
  administration causing prostate cancer (in animals), July, 398
  -induced changes in prostate cancer, July, 402
  therapy in prostate cancer, July, 450
ESWL (*see* Lithotripsy, extracorporeal shock wave)
Ether: methyl tert-butyl, for gallstones dissolution, Nov., 726
Extracorporeal
  carbon dioxide removal, evolution of concept of, Oct., 631–632
  hypothermic perfusion for in situ cooling of liver graft, Feb., 59
  life support *(see below)*
  shock wave lithotripsy (*see* Lithotripsy, extracorporeal shock wave)
Extracorporeal life support, Oct., 627–705
  arteriovenous, Oct., 634–636
  artificial lungs for (*see* membrane lungs for *below*)
  artificial organs for, future developments, Oct., 686–688
  blood activation in, Oct., 646–649
  cannulation for, Oct., 660–661
  carbon dioxide removal in, Oct., 641–643
  for cardiac failure, Oct., 681–685
    case selection, Oct., 681–682
    history, Oct., 633
    results, Oct., 684–685
    technique, Oct., 682–684
  catheters for, Oct., 658–660
  centers
    adult, in U.S., Oct., 692
    neonatal, Oct., 693–694
    pediatric, in U.S., Oct., 692–693
  circuit, planning and priming, Oct., 651
  clinical application, Oct., 666–686
    future developments, Oct., 691–692
  clinical practice, future developments, Oct., 688–689
  coagulation control during, Oct., 646–649
  current status, Oct., 633
  decannulation, Oct., 664–665
  future developments, Oct., 686–692
  gas exchange in, Oct., 639–643

heat exchangers for, Oct., 660
hemodynamics in, Oct., 643–646
history, Oct., 628–633
influence of, Oct., 689–690
managing patient on, Oct., 662–663
membrane lungs for, Oct., 651–660
failure of, mechanisms, Oct., 656
gas transfer in, Oct., 652
oxygen delivery through, Oct., 654
pathophysiology of, Oct., 656–657
perfusion abnormalities in, Oct., 656–657
ventilation abnormalities in, Oct., 657
ventilation/perfusion mismatch in, Oct., 657
modes of, Oct., 634–635
monitoring during, Oct., 661–662
oxygen consumption during, Oct., 641
oxygen delivery in, Oct., 639–641
pathophysiology, Oct., 634–651
patient care on, Oct., 663–664
physiology, Oct., 634–651
platelet aggregates during, Oct., 648
pumps for, Oct., 657–658
future developments, Oct., 687
for respiratory failure, in adults, history of, Oct., 630–631
for respiratory failure, in adults and older children, Oct., 676–681
patient selection, Oct., 677–678
results, Oct., 679, 680–681
technique, Oct., 678–680
for respiratory failure, in newborn, Oct., 666–676
cases in last decade, Oct., 666
catheter placement, chest x-rays of, Oct., 670
complications, Oct., 673–674, 675
follow-up studies, Oct., 676
history, Oct., 632–633
outcome, Oct., 675
patient care, Oct., 672–673
patient selection, Oct., 667–669
physiologic characteristics during, Oct., 671
results, Oct., 674–676
survival rates, Oct., 675
technique, Oct., 669–672
for shock
hemorrhagic, Oct., 685
septic, Oct., 686
team, Oct., 665
techniques, Oct., 651–665
tubing for, Oct., 658–660
venoarterial, Oct., 634–635
arterial pulse pressure and total blood flow during, Oct., 644
for liver transplantation, Feb., 76
major differences between venovenous ECLS and, Oct., 646
venovenous, Oct., 634–635
for liver transplantation, Feb., 73–76
major differences between venoarterial ECLS and, Oct., 646
weaning, Oct., 664–665
Extubation: transfer from intensive care after, Aug., 516

F

Facial
nerve
anatomic relationships of parotid and submandibular glands to, Dec., 782
main trunk, landmarks for identification of, Dec., 824
vessels and muscles, anatomic relationships of parotid and submandibular glands to, Dec., 782
Famotidine: in Zollinger-Ellison syndrome, June, 331
Fasting tests
in insulinoma, June, 340–341

Fasting tests *(cont.)*
in Zollinger-Ellison syndrome, June, 322
Fat: diet high in, and prostate cancer, July, 396
Ferritin: serum, in neuroblastoma, Sept., 592
Fetal alcohol syndrome: and neuroblastoma, Sept., 597
Fibrinolysis: defective, and thrombosis in liver transplantation, in children, Feb., 99
Fibrolamellar hepatoma: liver transplant for, Apr., 206
Fistula
arteriovenous (*see under* Vascular access for hemodialysis, maintenance)
biliary-vascular, after liver transplantation, Apr., 200–201
Eck model, for study of cyclosporine in liver transplantation, Mar., 141
FK 506 in liver transplantation, Mar., 141–150
biopsy results before and after, Mar., 146
effect on "rogue" clones, Mar., 144
liver function test response to, Mar., 146–147
renal function after, Mar., 148–149
results, Mar., 145
Flap: skin or myocutaneous, for coverage of exposed hemodialysis graft, Jan., 40
Fluid
flux across semipermeable membrane, Starling forces governing, Aug., 522
therapy in surgical critical care, Aug., 481
5-Fluorouracil
in insulinoma, June, 347
in rectal cancer, May, 282, 283, 284, 290, 291
combined with radiotherapy, May, 288
in somatostatinoma, June, 367
in VIPoma, June, 363
in Zollinger-Ellison syndrome, June, 334
Flushing: in VIPoma, June, 360
Flutamide: in prostate cancer, July, 451–452
Fractional excretion of sodium: calculation of, Aug., 527
Fractures
pubic rami, radiography of, Aug., 474
rib, chest radiography of, Aug., 473
Fungal infections: after liver transplantation, Apr., 187–188

G

Gallbladder
conduit biliary reconstruction after liver transplantation, Waddell-Calne, Feb., 90
typical complication with, Feb., 91
disease, role of lithotripsy in, Nov., 761–763
edema, ultrasound of, Aug., 542
sclerosis for prevention of stone formation, Nov., 763
sludge, ultrasound of, Aug., 542
stones (*see* Gallstones)
Gallstones, Nov., 717–721
chenodeoxycholic acid for (*see* Chenodeoxycholic acid for gallstones)
cholesterol, pathogenesis, Nov., 718–721
dissolution, Nov., 721–726
contact, Nov., 726
historical aspects, Nov., 721–722
oral, Nov., 725
oral, effects on cholesterol saturation in bile, Nov., 723
oral, recurrence after, Nov., 759–760
recurrence after, life table analysis, Nov., 759
effect of shock waves on, Nov., 734–736

lithotripsy of (*see* Lithotripsy, extracorporeal shock wave, of gallstones)
lithotripters, Nov., 728
recurrence, Nov., 758–761
after dissolution, life table analysis, Nov., 759
gallbladder sclerosis for prevention of, Nov., 763
in somatostatinoma, June, 367
ursodeoxycholic acid for (*see* Ursodeoxycholic acid for gallstones)
Ganciclovir: for cytomegalovirus infection after liver transplant, Apr., 189
Ganglioneuroblastoma: neuroblasts and maturing ganglion cells in, Sept., 587
Ganglioneuroma: maturation, Sept., 588
Ganglioside: Gd_2, in neuroblastoma, Sept., 592
Gas
blood (*see* Blood, gas)
exchange in extracorporeal life support, Oct., 639–643
transfer in membrane lungs during extracorporeal life support, Oct., 652
Gastrin
hypersecretion in Zollinger-Ellison syndrome, June, 323–324
levels in Zollinger-Ellison syndrome, June, 323
Gastrinoma (*see* Zollinger-Ellison syndrome)
Gastritis: stress, in critically ill, Aug., 554–556
Gastrointestinal complications: of external beam radiotherapy in prostate cancer, July, 445
Gd_2 ganglioside: in neuroblastoma, Sept., 592
Gene rearrangement analysis: for Epstein-Barr virus disorders after liver transplant, Apr., 193
Genetic predisposition: to prostate cancer, July, 397
Genetics: of neuroblastoma, Sept., 591
Geographic patterns: of prostate cancer, July, 395
GIPoma, June, 370
Gleason grading system: for prostate cancer, July, 402
Globulin
antilymphocyte, in liver transplantation, Mar., 138, 139
hyperimmune, for prevention of cytomegalovirus infection after liver transplant, Apr., 189
Glossitis: in glucagonoma, June, 351
Glucagon
in insulinoma, June, 346
values in glucagonoma diagnosis, June, 352
Glucagonoma, June, 347–356
anatomy, June, 348–349
angiography in, June, 353–354
clinical presentation, June, 350–352
dermatitis in, necrolytic migratory, June, *Color Plates* at 344
diagnosis, June, 352–354
epidemiology, June, 347–348
histology, June, 348–349
localization, June, 352–354
necrosis between stratum corneum and Malpighian layer in, June, *Color Plate* at 344
pancreatic distribution, June, 348
pathobiology, June, 349–350
stomatitis of, June, *Color Plate* at 344
surgery in, June, 354–355
treatment, June, 354–356
vulvovaginitis in, June, *Color Plate* at 344
Glucose
autoregulation in insulinoma, June, 338–339
intolerance
in glucagonoma, June, 350–351
in somatostatinoma, June, 366
in VIPoma, June, 360
solutions, oral, in VIPoma, June, 362

Graft
fistula for hemodialysis (*see* Vascular access for hemodialysis, maintenance, arteriovenous graft fistula for)
portal vein, antepancreatic, in liver transplantation, Feb., 86
-vs.-host disease after liver transplantation, Mar., 163
Granulomas: in liver allograft due to adenovirus, Apr., 194
Growth hormone-releasing factor-secreting tumors: of pancreas, June, 370
Guaiac-based tests: in rectal cancer, May, 249
Guanase: serum, and liver transplant rejection, Mar., 157

H

H_2-blockers (*see* Histamine$_2$-blockers)
Heart
(*See also* Cardiac)
cardiopulmonary bypass (*see* Extracorporeal life support)
cardiovascular symptoms in insulinoma, June, 339
failure, congestive, Aug., 518–520
central venous pressure in diagnosis of, Aug., 528–529
complicating vascular access for hemodialysis, Jan., 36
pulmonary edema and, Aug., 519–523
failure, extracorporeal life support for (*see* Extracorporeal life support, for cardiac failure)
physiology during extracorporeal life support, Oct., 650
transplantation, extracorporeal life support after, in children, Oct., 683
Heat exchangers: for extracorporeal life support, Oct., 660
Height: nomogram relating height and weight to body surface area, Aug., 498
Hemangioendothelioma: epithelioid, liver transplant for, Apr., 206
Hemasite device: for hemodialysis, Jan., 28
Hematogenous dissemination: of prostate cancer, July, 404–406
Hematoma: subcutaneous, after gallstone lithotripsy, Nov., 751
Hematuria: after gallstone lithotripsy, Nov., 748, 749, 750, 751, 753
Hemoccult: in detection of rectal cancer, May, 249
Hemodialysis
acute, in critically ill, Aug., 538–541
vascular access for (*see* Vascular access for hemodialysis)
Hemodynamics: in extracorporeal life support, Oct., 643–646
Hemoglobin: reduced, determination of, Aug., 484
HemoQuant: in detection of rectal cancer, May, 249–250
Hemorrhage
intracranial, during extracorporeal life support for newborn respiratory failure, Oct., 673
prevention in recipient hepatectomy, Feb., 81
pulmonary, due to shock wave lithotripsy, Nov., 737
in Zollinger-Ellison syndrome, June, 320
Hemorrhagic shock: extracorporeal life support for, Oct., 685
Hemostasis in liver transplantation, Feb., 79
need for, Feb., 90–91
Heparin
during extracorporeal life support, Oct., 648
for staging pelvic lymphadenectomy in prostate cancer, July, 425–426
Hepatectomy (*see* Transplantation, liver, hepatectomy in)

Hepatic
(*See also* Liver)
artery
in liver transplant rejection, Mar., 157
perfusion, implantation of arterial system for, Jan., 14
right, originating from superior mesenteric artery, Feb., 64
thrombosis after liver transplantation, Feb., 96–98
thrombosis after liver transplantation, gross and microscopic features, Feb., 100
blood flow reduction causing liver graft failure, Feb., 99
enzyme increase and liver transplant rejection, Mar., 157
Hepatitis and liver transplantation (*see under* Transplantation, liver)
Hepatocanalicular cholestasis: after liver transplantation, Feb., 107
Hepatocellular
carcinoma, liver transplant for, Apr., 206
survival rates after, Apr., 207
necrosis in reperfusion biopsy, Feb., 105
Hepatocyte swelling: after liver transplantation, Feb., 107
Hepatoma: fibrolamellar, liver transplant for, Apr., 206
Herpes simplex hepatitis: after liver transplantation, Apr., 190–191
Heterograft: bovine carotid, for hemodialysis, Jan., 27–28
Histamine$_2$-blockers
in prevention of stress gastritis, Aug., 555–556
in Zollinger-Ellison syndrome, June, 330–331
Histocompatibility
complex antigens, major, in liver transplant rejection, Mar., 153–154
influence on liver transplantation, Apr., 201–202
HIV carrier state: human, and liver transplantation, Apr., 212–213
Homografts, vascular, for liver transplantation, Feb., 64–66, 67
placement of, Feb., 68
Homovanillic acid: in neuroblastoma, Sept., 591, 592
Hormone
action in nephron, Aug., 526
antidiuretic, effects on renal function, Aug., 525
etiology of prostate cancer, July, 398
growth hormone-releasing factor-secreting tumors of pancreas, June, 370
therapy in prostate cancer, July, 450–452
Huber needle: illustration, Jan., 13
Hydantoin: maternal use, and neuroblastoma, Sept., 597
Hygroma: cystic, liver transplantation for, Apr., 217
Hyperalimentation
in critically ill, Aug., 547–550
in oliguric renal failure, Aug., 535–536
Hypercalcemia
pancreatic islet cell tumors with syndrome related to, June, 369
in VIPoma, June, 360
Hyperglycemia: in VIPoma, June, 360
Hyperimmune globulin: for prevention of cytomegalovirus infection after liver transplant, Apr., 189
Hyperparathyroidism: in Zollinger-Ellison syndrome, June, 321
Hyperplasia: benign prostatic, and prostate cancer, July, 396
Hypertension
persistent pulmonary, extracorporeal life support for, Oct., 667
venous, complicating vascular access for hemodialysis, Jan., 34, 35

Hypoaminoacidemia: in glucagonoma, June, 349, 351
Hypochlorhydria
in somatostatinoma, June, 366
in VIPoma, June, 360
Hypoglycemia
in insulinoma, June, 339–340
in somatostatinoma, June, 366
Hypophosphatemia: in VIPoma, June, 360
Hypothermia: for donor hepatectomy, Feb., 57–58, 59
Hypovolemia, Aug., 530–535
resuscitation for, Aug., 532–535
Hypoxemia: and trauma, Aug., 476

I

Ifosfamide: in neuroblastoma, Sept., 603–604
Imaging
bone, in prostate cancer staging, July, 422
magnetic resonance (*see* Magnetic resonance imaging)
nuclear, of salivary gland tumors, Dec., 814–815
skeletal, in neuroblastoma, Sept., 601
Immune perioperative events (*see* Transplantation, liver, immune events in, perioperative)
Immunodeficiency
syndrome, acquired (*see* AIDS)
virus, human, carrier state, and liver transplantation, Apr., 212–213
Immunoglobulin gene rearrangement analysis: for Epstein-Barr virus disorders after liver transplantation, Apr., 193
Immunohistochemical analysis: of Epstein-Barr virus disorders after liver transplant, Apr., 193
Immunohistochemistry: of prostate cancer, July, 400
Immunology: of neuroblastoma, Sept., 591
Impotency
after prostatectomy, radical retropubic, July, 442
after radiotherapy, external beam, in prostate cancer, July, 445–446
Inborn errors of metabolism: liver transplantation for, Apr., 219–222
Incision
for recipient of liver transplant, Feb., 72
total midline, for multiple cadaveric organ procurement, Feb., 60
Incontinence: urinary, after radical prostatectomy, July, 442
Indomethacin: in VIPoma, June, 362
Inductive pathways: in liver transplant rejection, Mar., 153–155
Infection: complicating vascular access for hemodialysis, Jan., 33
Infectious
etiology of prostate cancer, July, 398
mononucleosis after liver transplant, Apr., 191
problems in liver transplantation, Apr., 187–194
Inflammatory conditions: of salivary gland, Dec., 787–790
Insulin
in glucagonoma, June, 350
/glucose ratio in insulinoma, June, 339
Insulinoma, June, 335–347
anatomy, June, 336–338
angiography in, June, 342
clinical presentation, June, 339–340
CT in, June, 343
diagnosis, June, 340–344
epidemiology, June, 336
histology, June, 336–338
localization, June, 341–344
pancreatic distribution, June, 337

Insulinoma, June *(cont.)*
pathobiology, June, 338–339
surgery for, June, 344–346
treatment, June, 344–347
ultrasound in, intraoperative, June, 344
Interferon: in VIPoma, June, 363
Interleukin-2
propagation of activated lymphocytes from biopsy specimens, Mar., 142
receptors, soluble, and liver transplant rejection, Mar., 157
Intestine
complications of external beam radiotherapy in prostate cancer, July, 445
polypeptide, vasoactive, role in VIPoma, June, 357–359
Intraabdominal abscess: in critically ill, Aug., 551–554
Intracranial hemorrhage: during extracorporeal life support for newborn respiratory failure, Oct., 673
Intraepithelial neoplasia: prostatic, July, 400, 402
Intubation in surgical critical care, Aug., 472-476
indications for, Aug., 473
Iodine
-MIBG in neuroblastoma, Sept., 601
-125 implantation radiotherapy for prostate cancer, July, 446–447
Iproplatin: in neuroblastoma, Sept., 603–604
^{192}Ir implantation radiotherapy: in prostate cancer, July, 448
Ischemia
cold, during liver transplantation, Feb., 101
warm, during liver transplantation, Feb., 100
Ischemic
injury causing liver allograft failure, Feb., 100–107
lesion, digital, due to steal syndrome, Jan., 36
Islet cell tumors: pancreatic, with syndrome related to hypercalcemia, June, 369
IVOX, Oct., 687

J

Jaundice
in critically ill, Aug., 543–544
in insulinoma, June, 340
in somatostatinoma, June, 367
Joint disruption: sacroiliac, radiography of, Aug., 474
Jugular vein puncture: for central venous catheterization, Jan., 9

K

Kidney
failure
acute, Aug., 523–528
index, calculation of, Aug., 527
oliguric, Aug., 535–536
oliguric, hyperalimentation in, Aug., 536–537
function after cyclosporine and FK 506 in liver transplantation, Mar., 148–149
glucagonoma in, June, 348
stones, shock wave lithotripsy, Nov., 727
transplantation (*see* Transplantation, kidney)
vascular architecture after reperfusion of inadequately preserved kidneys, Feb., 103
Kinetics: oxygen, Oct., 636–638
Kraske's transsacral approach: for local excision of rectal cancer, May, 269
Kupffer cells: in liver transplantation, Mar., 125
Kussmaul's disease, Dec., 790

L

Lactate dehydrogenase: in neuroblastoma, Sept., 593
Laënnec's cirrhosis: liver transplant for, Apr., 209

Laparoscopic cholecystectomy, Nov., 762
Laser
ablation of rectal cancer, May, 271
lithotripsy for bile duct stones, Nov., 755
Leuprolide: in prostate cancer, July, 451–452
Levamisole: in rectal cancer, May, 283, 284
Life support, extracorporeal (*see* Extracorporeal life support)
Light microscopy: of neuroblastoma, Sept., 586–587
Limb: lower, arteriovenous fistula, for hemodialysis, Jan., 24
Lithium carbonate: in VIPoma, June, 362–363
Lithotripsy
biliary, Nov., 717–772
electrohydraulic, of bile duct stones, Nov., 755
extracorporeal shock wave (*see below*)
mechanical, of bile duct stones, Nov., 755
Lithotripsy, extracorporeal shock wave
of bile duct stones, Nov., 753–757
criteria for, Nov., 756
indications for, Nov., 755–756
results, Nov., 757
summary, Nov., 757
technique, Nov., 756–757
in gallbladder disease, Nov., 761–763
of gallstones
analgesia for, Nov., 747
application of shock waves, Nov., 746–747
coupling for, Nov., 743–744
effect of stone characteristics on, Nov., 741
history, Nov., 727–729
methyl tert-butyl ether after, Nov., 726
positioning for, Nov., 743, 744–745
postoperative care, Nov., 747–748
preoperative preparation for, Nov., 742–743
results, clinical, Nov., 748–753
selection of patients for, Nov., 738–741
stone recurrence after, Nov., 760–761
summary, Nov., 762–763
targeting in, Nov., 744, 746
technique, Nov., 742–748
history, Nov., 727–729
of kidney stones, history, Nov., 727
Lithotripter(s), Nov., 731–734
coupling, Nov., 733
Dornier, Nov., 753
efficacy of fragmentation, Nov., 738
gallstone, Nov., 728
Medstone, Nov., 749
shock wave generation by, Nov., 731–733
shock waves and, history, Nov., 727
Siemens, Nov., 750
Technomed International, Nov., 752
treatment head and spark gap electrode, photograph of, Nov., 734
visualization and, Nov., 733–734
Liver
(*See also* Hepatic)
abscess, CT-guided percutaneous drainage of, Aug., 553
biopsy (*see* Biopsy, liver)
cancer (*see* Cancer, liver)
disease
end-stage chronic, transplant for, Apr., 216–217
polycystic, transplant for, Apr., 217
dysfunction in surgical critical care, Aug., 543–547
failure, fulminant, transplant for, Apr., 214–216
survival rates, Apr., 215
function
during extracorporeal life support, Oct., 650

test response to FK 506 in liver transplantation, Mar., 146–147
metastases (*see under* Metastases)
retransplantation, Apr., 217–219
survival after, Apr., 219
transplantation (*see* Transplantation, liver)
Lung
(*See also* Pulmonary)
artificial (*see* Extracorporeal life support, membrane lungs for)
membrane (*see* Extracorporeal life support, membrane lungs for)
metastases from rectal cancer, reoperation for, May, 279
gross pathologic appearance in patient who died of ARDS, Aug., 559
infiltrates, diffuse fluffy, x-ray of, Aug., 519
membrane (*see* Extracorporeal life support, membrane lungs for)
volume during pressure support, Aug., 512
Luteinizing hormone releasing hormone agonist: in prostate cancer, July, 450–451
Lymph node
cervical, metastases to (*see* Metastases, to lymph nodes, cervical)
evaluation in prostate cancer, July, 423–427
CT for, July, 424
lymphangiography for, July, 423–424
MRI for, July, 424
sampling in neuroblastoma, Sept., 608
Lymphadenectomy, pelvic
lateral, extent in rectal cancer, May, 258–259
staging, in prostate cancer, July, 424–426
Lymphangiography: in prostate cancer, July, 423–424
Lymphatic spread: of prostate cancer, July, 404
Lymphedema: after external beam radiotherapy in prostate cancer, July, 445
Lymphocyte(s)
from biopsy specimens
culture and exposure to donor cells, Mar., 142
propagation with interleukin-2, Mar., 142
clonal expansion, Mar., 142
effect of cyclosporine on, Mar., 143
T, in liver transplant rejection, Mar., 155
Lymphocytosis: in liver transplant rejection, Mar., 157
Lymphoepithelial lesion: of salivary glands, Dec., 787–789
Lymphoid tissue: donor, persistence in liver grafts, Mar., 163
Lymphoma: B-cell, after liver transplantation, Apr., 192
Lymphoproliferative
disease, Epstein-Barr viral, after liver transplant, Apr., 191–193
tumors after liver transplant, Apr., 192
Lymphotoxic antibodies: in liver transplant, Mar., 125

M

Macrophage system: host, effect of liver transplantation on, Apr., 188
Magnetic resonance imaging
for lymph node evaluation in prostate cancer, July, 424
of neuroblastoma, Sept., 602
of parotid gland tumor, benign mixed, Dec., 819
in prostate cancer staging, July, 417
in rectal cancer staging, preoperative, May, 250
of salivary gland tumors, Dec., 815–819

Malignancy (*see* Cancer)
Malnutrition: in hemodialysis patients, Aug., 541
Malpighian layer: necrosis between stratum corneum and, in glucagonoma, June, *Color Plate* at 344; 351
Mannitol: in fulminant hepatic failure, Apr., 215
Marrow
  aplasia and hepatitis after liver transplant, Apr., 198
  transplantation for inborn errors of metabolism, Apr., 222
Maternal use: of hydantoin, and neuroblastoma, Sept., 597
Medstone lithotripter, Nov., 749
Membrane
  lungs (*see* Extracorporeal life support, membrane lungs for)
  semipermeable, Starling forces governing fluid flux across, Aug., 522
MEN I, June, 311–312
  gastrinoma in, June, 317–318
  insulinoma in, June, 336
  in Zollinger-Ellison syndrome, treatment, June, 334–335
Mental status: in surgical critical care, Aug., 541
Mesenteric artery
  inferior, ligation in lower anterior resection for rectal cancer, May, 258
  superior, right hepatic artery originating from, Feb., 64
Mesorectal dissection: in lower anterior resection for rectal cancer, May, 257–258
Metaiodobenzylguanidine: iodine-, in neuroblastoma, Sept., 601
Metastases
  insulinoma, treatment, June, 347
  liver
    chemotherapy of, totally implantable arterial access system for, Jan., 15
    transplantation for, Apr., 207
  to lymph nodes, cervical
    from parotid carcinoma, Dec., 828, 829
    from salivary gland carcinoma, minor, Dec., 828, 830
    from salivary gland tumors, Dec., 828
    from submandibular carcinoma, Dec., 828, 829
  from neuroblastoma, Sept., 589–590
  to parotid gland, Dec., 799
    from breast carcinoma, Dec., 808
    from skin carcinoma, squamous cell, Dec., 809
  from parotid gland adenocarcinoma, Dec., 797
  from polypeptidoma, pancreatic, June, 368
  prostate cancer (*see* Cancer, prostate, metastatic)
  from rectal cancer
    isolated, reoperation for, May, 273–274, 278–279
    liver, reoperation for, May, 278–279
    lung, reoperation for, May, 279
  from salivary gland carcinoma, adenoid cystic, treatment, Dec., 833
  from somatostatinoma, June, 364
  Zollinger-Ellison syndrome, June, 321
    treatment, June, 334
Methotrexate: in rectal cancer, May, 288–289
Methyl-CCNU: in rectal cancer, May, 288
Methyl tert-butyl ether: for gallstone dissolution, Nov., 726
MHC antigens: in liver transplant rejection, Mar., 153–154
MIBG imaging: iodine-, in neuroblastoma, Sept., 601
Microembolization: during extracorporeal life support, Oct., 650–651
Microglobulin: beta-2, and liver transplant rejection, Mar., 157

Microscopy
electron
of neuroblast, Sept., 589
in pancreatic endocrine tumor diagnosis, June, 315
light, of neuroblastoma, Sept., 586–587
Microvascular injury: causing liver transplantation failure, Feb., 99–100
MK-906: in prostate cancer, July, 452
M number
for tubing and catheters in extracorporeal life support, Oct., 660
in vascular access devices, Oct., 659
Model: Eck fistula, for study of cyclosporine in liver transplantation, Mar., 141
Monitor(s): commonly used in critical care, normal values obtained from, Aug., 475
Monitoring
of cyclosporine in liver transplantation, Mar., 139–140
during extracorporeal life support, Oct., 661–662
Monoclonal antibodies (*see* Antibodies, monoclonal)
Mononucleosis: infectious, after liver transplant, Apr., 191
Mortality
of multiple organ failure, Aug., 557
of neuroblastoma, Sept., 580
operative, of nerve-sparing radical prostatectomy, July, 442–443
of renal failure, oliguric, Aug., 535
risk of extracorporeal life support for respiratory failure
in adults and older children, Oct., 677
in newborn, Oct., 668
MRI (*see* Magnetic resonance imaging)
Mucocele prevention: in liver transplantation, Feb., 89
Mucoepidermoid carcinoma: of parotid gland, Dec., 795–796
Multiple endocrine neoplasia I (*see* MEN I)
Multiple organ failure, Aug., 517–560
Multiple organ transplantation (*see* Transplantation, multiple organ)
Muscles: facial, anatomic relationships of parotid and submandibular glands to, Dec., 782
Myocutaneous flap: for coverage of exposed hemodialysis graft, Jan., 40

N

Nausea: after gallstone lithotripsy, Nov., 753
Neck dissection: in salivary gland carcinoma, Dec., 827–830
Necrolytic migratory dermatitis: in glucagonoma, June, *Color Plates* at 344; 351
Necrosis
hepatocellular, in reperfusion biopsy, Feb., 105
between stratum corneum and Malpighian layer in glucagonoma, June, *Color Plate* at 344; 351
tubular, acute, Aug., 523
histologic appearance of, Aug., 524
Necrotizing sialometaplasia, Dec., 787
Needle: Huber, illustration, Jan., 13
Neoplasia (*see* Tumor)
Neopterin levels: after liver transplant, Mar., 157
Nephron: diagram of, Aug., 526
Nephrotoxicity: of cyclosporine, Mar., 139
Nerve, facial (*see* Facial, nerve)
Nervous system
embryologic development, stages of, Sept., 582

Nervous system *(cont.)*
sympathetic
in children, schematic of, Sept., 586
primitive, development of, Sept., 585
Neuroblast: electron microscopic picture of, Sept., 589
Neuroblastoma, Sept., 579–620
abdominal, physical findings, Sept., 599–600
biologic markers, Sept., 591–593
biology, Sept., 580–593
cellular, Sept., 591
cervical, Sept., 599
chemotherapy in (*see* Chemotherapy, in neuroblastoma)
CT scan of, Sept., 602
diagnosis, Sept., 597–602
embryology, Sept., 580–584
epidemiology, Sept., 580
ganglioneuroblastoma, neuroblasts and maturing ganglion cells in, Sept., 587
genetics, Sept., 591
high-risk, treatment, Sept., 612
historical background, Sept., 579–580
history, Sept., 597–599
immunology, Sept., 591
incidence, Sept., 580, 581
in situ, Sept., 583
intermediate-risk, treatment, Sept., 611–612
laboratory examinations, Sept., 600–601
low-risk, treatment, Sept., 611
management, Sept., 602–610
general principles, Sept., 602–603
operative technique, Sept., 606–610
orbital metastasis of, Sept., 590
origin, Sept., 582
pathology, Sept., 584–590
physical findings, Sept., 599–600
POG stage A, treatment, Sept., 611
POG stage B, treatment, Sept., 611
POG stage C
age more than 1 year, treatment, Sept., 611–612
infant, treatment, Sept., 611
POG stage D
age more than 1 year, treatment, Sept., 612
infant, treatment, Sept., 611–612
POG stage Ds, treatment of, Sept., 613
radiotherapy in, Sept., 604–605
retroperitoneal, Sept., 599–600
"rosette" formation in, Sept., 588
sites, primary
by age, Sept., 584
schematic of, Sept., 586
staging, Sept., 593–597
Evans', Sept., 593
International Staging System, proposed, Sept., 596
minimal evaluation for, Sept., 600
Pediatric Oncology Group, Sept., 594
St. Jude's, Sept., 594
TNM, Sept., 595–596
surgery, Sept., 606
complications of, Sept., 610
symptoms, Sept., 598
thoracic, Sept., 599
treatment
definitions of response to, Sept., 597
future directions for, Sept., 613–614
risk-related, Sept., 610–613
vascular, unresponsive, Sept., 587
Neurofibromatosis: pheochromocytoma and duodenal somatostatinomas, June, 364–365
Neurologic symptoms: in insulinoma, June, 339
Neuron-specific enolase: in neuroblastoma, Sept., 592
Neurotensinoma syndrome, June, 369–370
Newborn
extracorporeal life support centers for, Oct., 693–694
respiratory failure (*see* Extracorporeal life support, for respiratory failure, newborn)

N-myc oncogene amplification: in neuroblastoma, Sept., 591
Nomogram: relating height and weight to body surface area, Aug., 498
Nonsteroidal anti-inflammatory agents: effect on gallstone recurrence, Nov., 760
Nuclear scans: of salivary gland tumors, Dec., 814–815
Nutrition
  enteral, in critically ill, Aug., 548–550
  parenteral, total
    in critically ill, Aug., 547–549
    vascular access for, Jan., 8

O

Octreotide
  in glucagonoma, June, 355–356
  in insulinoma, June, 346
  in polypeptidoma, pancreatic, June, 368
  in VIPoma, June, 363
  in Zollinger-Ellison syndrome, June, 332
    metastatic, June, 334
OKT3 pretreatment: for multiple organ transplant, Apr., 223
Oliguria: in surgical critical care, Aug., 523–528
Oliguric renal failure, Aug., 535–536
  hyperalimentation in, Aug., 536–537
Omeprazole: in Zollinger-Ellison syndrome, June, 331–332
Oncocytoma, Dec., 795
Oncogene amplification: N-myc, in neuroblastoma, Sept., 591
Opsomyoclonus syndrome, Sept., 598
Orbital metastasis: of neuroblastoma, Sept., 590
Orchiectomy: in prostate cancer, July, 450
Organ(s)
  artificial, for extracorporeal life support, Oct., 686–688
  failure, multiple, Aug., 517–560
  multiple, transplant of (*see* Transplantation, multiple organ)
  supply for liver transplantation, Apr., 228–229
Osteoblastic metastases: from prostate cancer, July, 405
Osteolytic metastases: from prostate cancer, July, 405
Oximetry: pulse, Aug., 484–485
Oxygen
  concentration, inspired, Aug., 482–485
    complications of, Aug., 503–504
  consumption, Oct., 636
    during extracorporeal life support, Oct., 641
    index, calculation of, Aug., 501, 502
    relationships between oxygen delivery and, Oct., 638
  delivery
    in extracorporeal life support, Oct., 639–641
    through membrane lung, Oct., 654
    relationships between oxygen consumption and, Oct., 638
    systemic, Oct., 636–637
  kinetics, Oct., 636–638
  measurement in blood, Oct., 637
  partial pressure measurement, Aug., 483
  in septic patient, Aug., 489–490
  supplemental, during postextubation period, Aug., 515
  transport index, calculation of, Aug., 501–502
Oxygenation, extracorporeal (*see* Extracorporeal life support)
Oxygenator failure: during extracorporeal life support, in newborn, Oct., 673–674
Oxyhemoglobin: determination of, Aug., 484

P

Pain
  abdominal, in somatostatinoma, June, 367

Pain *(cont.)*
in Zollinger-Ellison syndrome, June, 320
Pancreas
adrenocorticotropinomas, June, 369
distribution
of glucagonoma, June, 348
of insulinoma, June, 337
of somatostatinoma, June, 364
of VIPoma, June, 358
polypeptidoma, June, 368–369
somatostatinoma (*see* Somatostatinoma)
tumors, functional endocrine, June, 309–386
amine precursor uptake and decarboxylation and, June, 309–311
comparison of, June, 313
general comments, June, 312–316
histology, June, 314
MEN I and, June, 311–312
rare, June, 368–369
tumors, growth hormone-releasing factor secreting, June, 370
tumors, neurotensin producing-, June, 369–370
Pancreatitis
acute, after gallstone lithotripsy, Nov., 748, 749, 751, 752, 753
pulmonary deterioration and, Aug., 517–518
Papillon's endocavitary irradiation: for rectal cancer, May, 271–272
Parenteral nutrition (*see* Nutrition, parenteral)
Parotid gland
adenocarcinoma, Dec., 797
clinical presentation, Dec., 807
adenoma, monomorphic, Dec., 795
anatomic relationships to facial nerve, vessels, and muscles, Dec., 782
anatomy and physiology, Dec., 781–785
carcinoma (*see* Carcinoma, parotid gland)
lobectomy, superficial, technique, Dec., 822–825
metastases to (*see* Metastases, to parotid gland)
oncocytoma, Dec., 795
rhabdomyosarcoma in, embryonal, in children, Dec., 802
tumors, Dec., 793–799
accessory, clinical presentation, Dec., 806
benign, Dec., 793–795
benign, distribution, Dec., 794
benign, mixed, Dec., 793–794
benign, mixed, clinical presentation, Dec., 804, 805
benign, mixed, CT sialogram of, Dec., 818
benign, mixed, MRI of, Dec., 819
clinical presentation, Dec., 803–809
deep lobe, clinical presentation, Dec., 806
deep lobe, CT of, Dec., 817
lobectomy for, superficial, technique, Dec., 822–825
malignant, Dec., 795–799
malignant, distribution, Dec., 796
malignant, mixed, Dec., 796–797
parotidectomy for, total and radical total, Dec., 822–825
treatment, Dec., 820–825
Parotidectomy: total and radical total, Dec., 822–825
Parotitis
"acute postoperative," Dec., 787
chronic recurrent, sialogram of, Dec., 814
^{103}Pd implantation radiotherapy: in prostate cancer, July, 448
PEEP, Aug., 478–479, 487–488
Pelvic
abscess, ultrasound of, Aug., 552
lymphadenectomy (*see* Lymphadenectomy, pelvic)
Pepcid: in Zollinger-Ellison syndrome, June, 331

Peptichemio: in neuroblastoma, Sept., 603
Perfusion
abnormalities in membrane lungs during extracorporeal life support, Oct., 656–657
ex vivo, for liver preservation, Feb., 67
hepatic artery, implantation of arterial system for, Jan., 14
/ventilation mismatch in membrane lungs during extracorporeal life support, Oct., 657
Perineal prostatectomy: radical, July, 443
Peritoneal dialysis: acute, Aug., 538–541
Petechiae: cutaneous, after gallstone lithotripsy, Nov., 748, 749, 751
Pheochromocytoma: duodenal somatostatinomas, and neurofibromatosis, June, 364–365
PHM: in VIPoma, June, 359
Phosphatases: serum, for prostate cancer staging, July, 419–421
Physics: of shock waves, Nov., 729–731
Physiologic
characteristics during extracorporeal life support for respiratory failure, in newborn, Oct., 671
consequences of ARDS, Aug., 517
Pigment gallstones, Nov., 717
Platelet
aggregates during extracorporeal life support, Oct., 648
changes during liver transplantation, Feb., 91
transfusions in liver transplantation, Mar., 126
Pneumothorax: and PEEP, Aug., 503
Polycystic disease: hepatic, transplantation, for, Apr., 217
Polymyxin B: for endotoxemia in liver transplantation, Mar., 136
Polypeptide: vasoactive intestinal, role in VIPoma, June, 357–359
Polypeptidoma: pancreatic, June, 368–369
Polytetrafluoroethylene graft for hemodialysis, Jan., 28
aneurysm in, Jan., 34
patency rate, Jan., 30
Portal
triad crossclamping in recipient hepatectomy, Feb., 80
vein
graft, antepancreatic, in liver transplantation, Feb., 86
infusion chemotherapy in rectal cancer, May, 289–291
sampling, intraoperative, in insulinoma, June, 343
sampling, percutaneous transhepatic, in insulinoma, June, 342–343
sampling, percutaneous transhepatic, in Zollinger-Ellison syndrome, June, 324, 328–329
thrombosis (*see* Thrombosis, portal vein)
Positive end-expiratory pressure, Aug., 478–479, 487–488
Positive pressure ventilation: airway pressure curve for, Aug., 478
Potassium: in UW solution for liver preservation, Feb., 71
Potency-sparing radical prostatectomy (*see* Prostatectomy, radical, for prostate cancer, retropubic, potency-sparing)
Prednisone
in liver transplantation, survival rates after, Apr., 203
in VIPoma, June, 362
Preservation of liver grafts (*see* Transplantation, liver, preservation for)
Priapism: extracorporeal life support in, Oct., 686
Prostaglandin E
levels in VIPoma, June, 359
in liver failure, fulminant, Apr., 215–216
Prostate
adenocarcinoma (*see* Adenocarcinoma, prostate)

Prostate *(cont.)*
anatomy, zonal, July, 398–399
cancer (*see* Cancer, prostate)
hyperplasia, benign, and prostate cancer, July, 396
neoplasia, intraepithelial, July, 400, 402
resection
(*See also* Prostatectomy)
transurethral, repeat, for stage TA1 prostate cancer, July, 418
specific antigen (*see* Antigen, prostate specific)
Prostatectomy, radical, for prostate cancer, July, 437–444
perineal, July, 443
retropubic, potency-sparing, July, 439–443
complications, early, July, 441–442
complications, late, July, 442–443
dissection of prostatic apex from neurovascular bundles during, July, 441
operative technique, July, 439–440, 441
preoperative preparation, July, 439
results, July, 440–441
salvage, for radiation failures, July, 443–444
technical considerations, July, 437–444
Prostin: in fulminant hepatic failure, Apr., 215–216
Protein
amyloid A, and liver transplant rejection, Mar., 157
C deficiency and thrombosis in liver transplantation, in children, Feb., 99
metabolism during extracorporeal life support, Oct., 650
Pseudo-Kaposi's sarcoma: complicating vascular access for hemodialysis, Jan., 36
PTFE graft (*see* Polytetrafluoroethylene graft)
Pubic rami fractures: radiography of, Aug., 474
Pulmonary
(*See also* Lung)
artery catheter (*see* Catheter, pulmonary artery)
deterioration and pancreatitis, Aug., 517–518
edema
associated with ARDS, Aug., 497–498
heart failure and, congestive, Aug., 519–523
high-pressure and low-pressure, comparisons of, Aug., 499
high-pressure and low-pressure, differentiation of, Aug., 522–523
high-pressure and low-pressure, treatment of, Aug., 500
embolism as complication of retropubic radical prostatectomy, July, 442
failure, Aug., 472–517
extracorporeal life support for (*see* Extracorporeal life support)
hemorrhage due to shock wave lithotripsy, Nov., 737
hypertension, persistent, extracorporeal life support for, Oct., 667
vascular resistance index, calculation of, Aug., 501
Pulse
oximetry, Aug., 484–485
pressure, arterial, during venoarterial cardiopulmonary bypass, Oct., 644
Pumps for extracorporeal life support, Oct., 657–658
future developments, Oct., 687
Pyelography: intravenous, with CT, in neuroblastoma, Sept., 600–601

Q

Quality of life: after liver transplantation, Apr., 225–227

R

Race
  gallstones and, Nov., 717
  liver transplantation and, Apr., 230
  prostate cancer and, July, 395
Radiation
  diagnostic (*see* Radiography)
  -induced salivary gland tumors, Dec., 792
  therapeutic (*see* Radiotherapy)
Radiography
  bone, for prostate cancer staging, July, 423
  chest
    of catheter placement for extracorporeal life support, in newborn, Oct., 670
    of lung infiltrates, diffuse fluffy, Aug., 519
    in prostate cancer staging, July, 418
    of rib fractures, Aug., 473
  in neuroblastoma, Sept., 600–601
    thoracic, Sept., 599
  of pubic rami fractures, Aug., 474
  of sacroiliac joint disruption, Aug., 474
  of salivary gland tumors, Dec., 813
Radiotherapy
  in neuroblastoma, Sept., 604–605
  in prostate cancer, July, 444–449
    external beam, July, 444–446
    external beam, for palliation of metastases, July, 448–449
    failure, salvage radical prostatectomy after, July, 443–444
    interstitial, July, 447–448
    interstitial, with iodine-125, July, 446–447
    technical considerations, July, 444–449
  in rectal cancer, May, 283–289
    chemotherapy combined with, May, 288–289
    endocavitary, May, 271–272
    intraoperative, May, 287–288
    postoperative, May, 286–287
    postoperative, combined with preoperative, May, 287
    preoperative, May, 285–286
    preoperative, combined with postoperative, May, 287
  in salivary gland tumors, Dec., 830–833
    adjuvant, Dec., 831–832
    adjuvant, postoperative, indications for, Dec., 832
    benign, Dec., 830–831
    palliative, Dec., 832–833
  in Zollinger-Ellison syndrome, June, 334
Ranitidine: in Zollinger-Ellison syndrome, June, 331
Rapamycin: in liver transplantation, Mar., 149
Rash: in pancreatic polypeptidoma, June, 368
Reconstruction
  of arterial anomalies in liver donor, Feb., 65, 66
  biliary (*see* Transplantation, liver, biliary reconstruction in)
  completed, in multiple organ transplant recipient, Apr., 225
Rectal cancer, May, 247–299
  adjuvant therapy for, May, 280–291
    hidden biases, May, 282
    major treatment deviations, May, 281
    sample size and duration of follow-up, May, 281
    subgroup or covariate analysis, May, 281–282
    use of historical controls, May, 281
  anastomosis for, coloanal, May, 262, 264, 265
  anastomosis for, hand-sewn vs. stapled, May, 259–260
  anastomosis for, practical aspects in choice of technique, May, 260–261
  anastomosis for, stapled
    double stapling technique, May, 263

Rectal cancer, May *(cont.)*
insertion of pursestring for, May, 261
insertion of stapler, May, 261–262
making the anastomosis, May, 262
preparation of bowel ends for, May, 261
selection of stapler size, May, 261
vs. hand-sewn, May, 259–260
chemotherapy in (*see* Chemotherapy, in rectal cancer)
detection, early, May, 247–250
electrocoagulation of, May, 268–271
eradication of, local, May, 265–273
evaluation of patients for, May, 266–267
options, May, 267
rationale, May, 265–266
selection of patients for, May, 266
surveillance after, May, 272–273
excision of, local, May, 267–268
Kraske's transsacral, May, 269
transanal, May, 268
York Mason's transsphincteric, May, 270
laser ablation of, May, 271
management, May, 247–299
metastases from (*see* Metastases, from rectal cancer)
operations, choice of, May, 252–273
primary, locally advanced, extended resection for, May, 279–280
radiotherapy in (*see* Radiotherapy, in rectal cancer)
recurrence, local, May, 274–278
based on stage of disease, May, 275
causes, May, 275–277
detection, May, 277
frequency, May, 274–275
reoperation for, May, 273–278
surgery for, May, 277–278
resection for, abdominoperineal, May, 273
resection for, abdominosacral, May, 265–266
resection for, lower anterior, May, 255–262
anastomosis for (*see* Rectal cancer, anastomosis for)
extent of distal margins in, May, 255–257
extent of lateral margins in, May, 257–258
extent of lateral pelvic lymphadenectomy in, May, 258–259
inferior mesenteric artery ligation in, May, 258
mesorectal dissection in, May, 257–258
screening, May, 247–250
sphincter-saving procedures for, May, 254–255
staging, preoperative, May, 250–252
by CT, May, 250
by MRI, May, 250
by ultrasound, endoluminal, May, 251–252, 253
Rectal examination, digital, in prostate cancer
for diagnosis, July, 406, 432, 433
for staging, July, 416–417
5-α Reductase inhibitors: in prostate cancer, July, 452
Renal (*see* Kidney)
Reperfusion
biopsy, hepatocellular necrosis in, Feb., 105
of kidney grafts, inadequately preserved, renal vascular architecture after, Feb., 103
Respiration: tissue, Oct., 636–638
Respiratory
distress syndrome, adult, Aug., 491–517
lungs in, gross pathologic appearance, Aug., 559
physiologic consequences of, Aug., 517

failure
(*See also* Surgical critical care)
extracorporeal life support for (*see* Extracorporeal life support, for respiratory failure)
Resuscitation: for hypovolemia, Aug., 532–535
Retransplantation, liver, Apr., 217–219
survival after, Apr., 219
Retroperitoneal neuroblastoma, Sept., 599–600
Retropubic prostatectomy (*see* Prostatectomy, radical, for prostate cancer, retropubic)
Revascularization: in liver transplantation, Feb., 85–88
Rhabdomyosarcoma: embryonal, presenting as parotid mass, in children, Dec., 802
Rhone Poulenc pump, Oct., 658
Rib fractures: chest radiography of, Aug., 473
Roentgenography (*see* Radiography)
"Rosette" formation: in neuroblastoma, Sept., 588

S

Sacroiliac joint disruption: radiography of, Aug., 474
Salivary gland(s)
carcinoma (*see* Carcinoma, salivary gland)
disease
non-neoplastic, simulating tumor-like manifestations, Dec., 786
systemic, Dec., 790–791
inflammatory conditions, Dec., 787–790
minor
anatomy and physiology, Dec., 785–786
tumors, clinical presentation, Dec., 810–811
tumors, malignant, distribution of, Dec., 801
tumors, mixed, Dec., 800–801
tumors, site distribution, Dec., 811
neoplasms (*see* tumors *below*)
normal, histologic structures, Dec., 781
pathology, Dec., 786–803
in Sjögren's syndrome, Dec., 788
tumors, Dec., 779–843
biopsy, fine-needle aspiration, Dec., 819–820
chemotherapy in, Dec., 833
in children, Dec., 802–803
clinical presentation, Dec., 803–811
CT of, Dec., 815–819
cure rates, by site of origin, Dec., 837
diagnostic studies, Dec., 812–820
distribution, Dec., 792
etiology, Dec., 791–793
histogenesis, bicellular theory of, Dec., 780
histologic classification, Dec., 793
incidence, Dec., 793
malignant, influence of nodal status on 5-year cure in, Dec., 828
of minor glands (*see* Salivary gland, minor, tumors)
MRI of, Dec., 815–819
nuclear scans of, Dec., 814–815
prognosis, effect of histologic subtype on, Dec., 835–840
prognosis, effect of site on, Dec., 834–835
prognosis, effect of stage on, Dec., 834, 835
prognosis, factors influencing, Dec., 834–840
radiotherapy in (*see* Radiotherapy, in salivary gland tumors)
sialography in, Dec., 814
soft tissue, Dec., 801–802
staging, Dec., 811–812
staging, TNM system, Dec., 813
treatment, Dec., 820–833
ultrasound in, Dec., 815
x-rays of, plain, Dec., 813

Salivary system: anatomy and physiology of, Dec., 779–786
Sandostatin (*see* Octreotide)
Sarcoma
pseudo-Kaposi's, complicating vascular access for hemodialysis, Jan., 36
salivary gland, Dec., 802
spindle cell, in upper abdomen, multiple organ transplant for, Apr., 223
Scan (*see* Imaging)
Sci-Med Kolobow lung, Oct., 654–655
Sclerosing cholangitis: after liver transplant, Apr., 212
Sclerosis: gallbladder, for prevention of stone formation, Nov., 763
Scribner shunt: for hemodialysis, Aug., 539, 540
Seizures: during extracorporeal life support, in newborn, Oct., 674
Seldinger technique: for pulmonary artery catheter placement, Aug., 493
Semustine: in rectal cancer, May, 282
Sepsis
in critically ill, Aug., 488–491, 550–554
after liver transplantation, Apr., 201
Septic
complications of central venous catheter, Jan., 9–10
shock, extracorporeal life support in, Oct., 686
Sexual
factors in epidemiology of prostate cancer, July, 397
impotency (*see* Impotency)
Shock
hemorrhagic, extracorporeal life support for, Oct., 685
septic, extracorporeal life support in, Oct., 686
wave(s), Nov., 729–738
effect on gallstones, Nov., 734–736
effect on tissue, Nov., 736–738
focal zone, Nov., 730–731
focal zone, waveform at, Nov., 729
generation by lithotripters, Nov., 731–733
lithotripsy (*see* Lithotripsy, extracorporeal shock wave)
lithotripters and, history, Nov., 727
medium, Nov., 730
physics of, Nov., 729–731
steepening, Nov., 730
Shunt: Scribner, for hemodialysis, Aug., 539, 540
Sialadenitis
acute, Dec., 787
suppurative or acute bacterial, Dec., 787
Sialography
Ct, of parotid gland tumor, Dec., 818
of parotitis, chronic recurrent, Dec., 814
in salivary gland tumors, Dec., 814
Sialometaplasia: necrotizing, Dec., 787
Sialopathy: obstructive, Dec., 790
Siemens lithotripter, Nov., 750
Sinusoidal lining cell damage: liver, due to cold preservation, Feb., 104
Situs inversus: liver transplantation for, Feb., 92–93
Sjögren's syndrome
CT in, Dec., 816
salivary gland enlargement in, Dec., 788
Skeletal imaging: in neuroblastoma, Sept., 601
Skin
carcinoma, squamous cell, metastatic to parotid gland, Dec., 809
flap for coverage of exposed hemodialysis graft, Jan., 40
petechiae after gallstone lithotripsy, Nov., 748, 749, 751

Slush preservation of liver graft, Feb., 67–69
UW solution for, Feb., 70–71
Snuff-box fistula for hemodialysis, Jan., 20–22
patency rate, Jan., 31
Sodium: fractional excretion of, calculation, Aug., 527
Soft tissue tumors: of salivary gland, Dec., 801–802
Somatostatin: role in somatostatinoma, June, 365–366
Somatostatinoma, June, 363–367
anatomy, June, 364–365
clinical presentation, June, 366–367
differential diagnosis, June, 367
epidemiology, June, 364–365
histology, June, 364–365
pancreatic distribution, June, 364
pathobiology, June, 365–366
surgery in, June, 367
treatment, June, 367
Sphincter-saving procedures: for rectal cancer, May, 254–255
Spindle cell sarcoma: upper abdominal, multiple organ transplant for, Apr., 223
Squamous cell parotid gland carcinoma, Dec., 798
fungating metastatic, Dec., 809
Stapled anastomosis for rectal cancer (*see* Rectal cancer, anastomosis for, stapled)
Starling forces: governing fluid flux across semipermeable membrane, Aug., 522
Steal syndrome: complicating vascular access for hemodialysis, Jan., 34–36
Steatorrhea: in somatostatinoma, June, 367
Steatosis: macrovesicular, in donor liver, causing graft failure, Feb., 95
Steroids in liver transplantation, survival rates after, Apr., 205
in children, Apr., 206
Stomatitis: of glucagonoma, June, *Color Plate* at 344; 351
Stones
bile duct
lithotripsy of (*see under* Lithotripsy)
treatment, newer methods, Nov., 755
treatment, standard, Nov., 754
gallstones (*see* Gallstones)
kidney, shock wave lithotripsy, Nov., 727
submaxillary gland, Dec., 791
Stratum corneum: necrosis between Malpighian layer and, in glucagonoma, June, *Color Plate* at 344; 351
Streptokinase: for salvage of hemodialysis vascular access, Jan., 39
Streptozotocin
in glucagonoma, June, 355
in insulinoma, June, 347
in pancreatic islet cell tumors with syndrome related to hypercalcemia, June, 369
in pancreatic polypeptidoma, June, 368
in somatostatinoma, June, 367
in VIPoma, June, 363
in Zollinger-Ellison syndrome, June, 334
Stress gastritis: in critically ill, Aug., 554–556
Strictures
anastomotic
avoidance in liver transplantation, Feb., 87
after prostatectomy, radical retropubic, July, 442
after liver transplantation due to hepatic artery thrombosis, Feb., 99
Subclavian vein puncture: for central venous catheterization, Jan., 8–9
Subcutaneous hematoma: after gallstone lithotripsy, Nov., 751
Sublingual gland(s)
anatomy and physiology, Dec., 785
tumors, Dec., 800

Sublingual gland(s) *(cont.)*
treatment, Dec., 827
Submandibular gland
adenocarcinoma, locally advanced high-grade, Dec., 810
anatomic relations to facial nerve, vessels, and muscles, Dec., 782
anatomy and physiology, Dec., 785
excision, technique, Dec., 826–827
stones, Dec., 791
tumors, Dec., 798–800
clinical presentation, Dec., 809–810
excision of, technique, Dec., 826–827
malignant, distribution, Dec., 800
treatment, Dec., 825–827
Submaxillary gland (*see* Submandibular gland)
Sucralfate: in prevention of stress gastritis, Aug., 556
Suramin: in prostate cancer, July, 453
Surgical critical care, Aug., 471–569
case report 1 (pulmonary failure), Aug., 472–517
case report 2 (multiple organ failure), Aug., 517–560
monitors in, normal values obtained from, Aug., 475
Sympathetic nervous system (*see* Nervous system, sympathetic)
Systemic vascular resistance index
calculation of, Aug., 500
units for reporting, Aug., 501

T

Tagamet: in Zollinger-Ellison syndrome, June, 330–331
Technomed International lithotripter, Nov., 752
Teneposide: in neuroblastoma, Sept., 603, 604
Therapeutic Intervention Scoring Systems, Aug., 557
Thermodilution cardiac output measurement, Aug., 497
Third space fluid accumulation, Aug., 481
Thoracic neuroblastoma, Sept., 599
Thrombectomy: for salvage of hemodialysis vascular access, Jan., 39–40
Thromboembolism: in glucagonoma, June, 351
Thrombolysis: for salvage of hemodialysis vascular access, Jan., 39
Thrombosis
complicating vascular access for hemodialysis, Jan., 32–33
hepatic artery, after liver transplantation, Feb., 96–98
gross and microscopic features, Feb., 100
portal vein
liver transplantation for, Apr., 209–210
after liver transplantation, Feb., 97
vascular, after liver transplantation, "medical" factors contributing to, Feb., 98–99
Thrombotic complications: of central venous catheter, Jan., 10
Tidal volume: in surgical critical care, Aug., 477–478
Tissue
effect of shock waves on, Nov., 736–738
respiration, Oct., 636–638
soft tissue tumors of salivary gland, Dec., 801–802
T lymphocytes: in liver transplant rejection, Mar., 155
Tomography (*see* Computed tomography)
Toxic injury: to allograft liver, Apr., 201
Tracheostomy
in mechanically ventilated patients, Aug., 508–509
tube, removal of, Aug., 516

Transfer: from intensive care after extubation, Aug., 516
Transfusions: blood and platelet, in liver transplantation, Mar., 126
Transplantation: bone marrow, for inborn errors of metabolism, Apr., 222
Transplantation: heart, extracorporeal life support after, in children, Oct., 683
Transplantation, kidney
  as prototype for liver transplantation, Mar., 137–141
  survival rates, Mar., 137
  vascular architecture after inadequate preservation for, Feb., 103
Transplantation, liver
  arterial anomalies in, donor, Feb., 64
    reconstruction of, Feb., 65, 66
  auxiliary, Apr., 227–228
  bacterial infections after, Apr., 187–188
  for benign disease, Apr., 207–210
  biliary complications after, pathologist's view, Apr., 199–201
  biliary reconstruction in, Feb., 88–90, 91
    Waddell-Calne, Feb., 90
    Waddell-Calne, typical complication with, Feb., 91
  biloma formation after, Feb., 98
  bypass in, venovenous, Feb., 73–76
  candidacy, Apr., 202–213
  cholangiolar proliferation after, Feb., 107
  cholangiolitis after, acute, Feb., 107
  cholestasis after, hepatocanalicular, Feb., 107
  for cirrhosis
    biliary, primary, survival after, Apr., 217
    Laënnec's, Apr., 209
  cooling for, core, Feb., 57–58
  with aortic infusion alone, Feb., 62–63
  in situ, by extracorporeal hypothermic perfusion, Feb., 59
  in multiple organ procurement, Feb., 58–61
  cooling for, initial, Feb., 57–66
  cooling for, subsequent (*see* preservation *below*)
  cyclosporine in (*see* Cyclosporine, in liver transplantation)
  cystic duct obstruction in, Feb., 88, 89
  development, Feb., 56–93
  drug injury in, differentiated from toxic injury, Apr., 201
  economic factors and, Apr., 229–230
  endotoxemia and, Mar., 129–136
  endotoxin levels in, Mar., 135
    (in dog), Mar., 134
  for end-stage chronic disease, Apr., 216–217
  Epstein-Barr virus disorders after, Apr., 191–193
  failure
    ischemic injury causing, Feb., 100–107
    microvascular injury causing, Feb., 99–100
    preexisting disease causing, Feb., 95–96
    steatosis in donor liver causing, macrovesicular, Feb., 95
    technical causes, Feb., 96–100
  FK 506 in (*see* FK 506 in liver transplantation)
  for fulminant hepatic failure, Apr., 214–216
    survival rates, Apr., 215
  fungal infections after, Apr., 187–188
  graft function after, early, Feb., 93–107
  graft-vs.-host disease after, Mar., 163
  hemostasis in, Feb., 79
    need for, Feb., 90–91
  hepatectomy in, donor, Feb., 57–66
    incision for, total midline, Feb., 60

Transplantation, liver *(cont.)*
hepatectomy in, recipient, Feb., 76–80
closure and hemostasis in, Feb., 79
crossclamping of portal triad in, Feb., 80
technique for removal of liver from above downward, Feb., 81
technique for removal of liver from below upward, Feb., 78, 79
hepatitis after
adenoviral, Apr., 193–194
autoimmune, Apr., 212
cytomegaloviral, Apr., 189–190
Epstein-Barr virus, Apr., 191–193
herpes simplex, Apr., 190–191
non-A, non-B, Apr., 198–199, 212
time of occurrence, Apr., 188
varicella-zoster, Apr., 190–191
viral, Apr., 188–195
viral, causes of, Apr., 188
hepatitis A virus after, Apr., 199
hepatitis B virus after, Apr., 195–198
hepatitis B virus carrier state and, chronic, Apr., 211–212
hepatitis viruses after, Apr., 195–199
for hepatocellular carcinoma, survival rates, Apr., 207
hepatocyte swelling after, Feb., 107
histocompatibility influence on, Apr., 201–202
HIV carrier state and, human, Apr., 212–213
hypothermia for, Feb., 57–58
immune events in, perioperative, Mar., 123–126
with ABO-compatible donors, Mar., 123–126
with ABO-incompatible donors, Mar., 126–129
for inborn errors of metabolism, Apr., 219–222
indications, Apr., 204
infectious problems in, Apr., 187–194
kidney transplantation as prototype for, Mar., 137–141
limitations, practical, Apr., 228–229
for malignant disease, Apr., 205–207
survival rates, Apr., 208
modifications of, Feb., 92–93
mucocele prevention in, Feb., 89
multiple previous operations and, Apr., 210–211
in older patients, Apr., 209
organ supply and, Apr., 228–229
original disease and, Apr., 202–213
outcome, Apr., 202–213
partial, in children, Feb., 92–93, 94
piggyback technique with preservation of vena cava, Feb., 80–84
formation of site for anastomosis, Feb., 83
steps in preparation of recipient vena cava for, Feb., 82
portal vein graft in, antepancreatic, Feb., 86
for portal vein thrombosis, Apr., 209–210
preservation for
ex vivo perfusion in, Feb., 67
means of, Feb., 66–71
slush, Feb., 67–69
slush, UW solution for, Feb., 70–71
solutions for, characteristics and constituents of, Feb., 69
procurement for, in non-heart-beating donors, Feb., 61–64
quality of life after, Apr., 225–227
recipient operation, Feb., 72–93
incision in, Feb., 72
reduced size techniques, Feb., 92–93, 94
rejection
acute cellular, clinicopathologic features, Mar., 155–160

acute cellular, histopathologic grading system of, Mar., 160
chronic, clinicopathologic features, Mar., 161–163
clinicopathologic features, Mar., 155–163
differential diagnosis, Mar., 150–163
effector pathways in, Mar., 155
histologic events in, early, Mar., 156
hyperacute, Mar., 123
hyperacute, diagnostic criteria, Mar., 129
inductive pathways in, Mar., 153–155
mechanisms underlying unique properties of liver allografts (in rat), Mar., 152–153
prevention, Mar., 136–150
tolerance induction and, Mar., 150–155
tolerance induction and (in rat), Mar., 151–152
retransplantation, Apr., 217–219
survival after, Apr., 219
revascularization in, Feb., 85–88
sepsis after, Apr., 201
for situs inversus, Feb., 92–93
strictures after, due to hepatic artery thrombosis, Feb., 99
strictures in, anastomotic, avoidance of, Feb., 87
survival rates, Apr., 203, 205, 207, 209
31-year perspective
Part I, Feb., 55–116
Part II, Mar., 123–178
Part III, Apr., 187–240
thrombosis after, vascular, "medical" factors contributing to, Feb., 98–99
timing of, Apr., 213–219
toxic injury in, differentiated from drug injury, Apr., 201
transplantation of other organs and, Apr., 222–225
vascular homografts for, Feb., 64–66, 67
placement of, Feb., 68
washing out of homograft in, technique, Feb., 85
in young patients, Apr., 209
Transplantation, multiple organ, Apr., 222–225
completed reconstruction in recipient, Apr., 225
core cooling in, Feb., 58–61
in situ, principle of, Feb., 61
removal of organ cluster graft from donor, Apr., 224
for sarcoma, spindle cell, Apr., 223
Trauma: and hypoxemia, Aug., 476
Tube
endotracheal (*see* Endotracheal tube)
tracheostomy, removal of, Aug., 516
Tubercidin: in Zollinger-Ellison syndrome, June, 334
Tubing: for extracorporeal life support, Oct., 658–660
Tubular necrosis, acute, Aug., 523
histologic appearance of, Aug., 524
Tumor
dumbbell, treatment of, Sept., 612–613
endocrine
multiple (*see* MEN I)
pancreatic (*see* Pancreas, tumors, functional endocrine)
lymphoproliferative, after liver transplant, Apr., 192
pancreas (*see* Pancreas, tumors)
parotid gland (*see* Parotid gland, tumors)
prostate intraepithelial, July, 400, 402
salivary gland (*see* Salivary gland, tumors)
sublingual gland (*see* Sublingual gland, tumors)
submandibular gland (*see* Submandibular gland, tumors)
Warthin's, Dec., 794–795
CT of, Dec., 816

U

Ulcer diasthesis: in Zollinger-Ellison syndrome, June, 320
Ulnar
artery, demonstration of supplementation to fistula flow by, Jan., 19
-basilic fistula for hemodialysis, Jan., 22–23
Ultrasound
of abscess, intraabdominal, Aug., 552–553
of bile duct dilation, Aug., 545
Doppler, of hepatic artery thrombosis after liver transplantation, Feb., 97
endoluminal, in rectal cancer staging, May, 251–252, 253
of gallbladder sludge and edema, Aug., 542
intraoperative
in insulinoma, June, 343, 344
in Zollinger-Ellison syndrome, June, 328
lithotripsy for biliary stones, Nov., 755
in neuroblastoma, Sept., 601
for prostate cancer staging, July, 417
in salivary gland tumors, Dec., 815
transrectal, in diagnosis of prostate cancer, July, 408, 410–411, 432–433
of vascular access for hemodialysis, Jan., 38
Umbilical vein graft: for hemodialysis, Jan., 27
Urinary
incontinence after radical prostatectomy, July, 442
tract complications of external beam radiotherapy in prostate cancer, July, 445
Urogram: excretory, for prostate cancer staging, July, 418
Ursodeoxycholic acid for gallstones, Nov., 725
historical aspects, Nov., 722
after lithotripsy, Nov., 763
mechanisms of action, Nov., 722–724
UW solution: for liver preservation, Feb., 70–71

V

Vanillymandelic acid: in neuroblastoma, Sept., 591–592
Vanishing bile duct syndrome: after liver transplant, Apr., 190
Varicella-zoster hepatitis: after liver transplantation, Apr., 190–191
Vascular
(*See also* Vessels)
access *(see below)*
homografts for liver transplantation, Feb., 64–66, 67
placement of, Feb., 68
resistance index
pulmonary, calculation of, Aug., 501
systemic (*see* Systemic vascular resistance index)
Vascular access, Jan., 7–48
devices, M number in, Oct., 659
for hemodialysis *(see below)*
for nonuremic patients *(see below)*
Vascular access for hemodialysis, Jan., 15–41
acute, Jan., 16–17
in critically ill, Aug., 539–540
indications, Jan., 15–16
Vascular access for hemodialysis, maintenance, Jan., 17–41
aneurysms complicating, Jan., 33–34
arteriovenous fistula for, direct, Jan., 20–25
antecubital, Jan., 23
brachiobasilic, Jan., 23–24, 25
brachiocephalic, Jan., 23
Brescia-Cimino, Jan., 20
Brescia-Cimino, patency rate, Jan., 31
lower limb, Jan., 24
patency rate, Jan., 29

sites for, Jan., 21
snuff-box, Jan., 20–22
snuff-box, patency rate, Jan., 31
ulnar-basilic, Jan., 22–23
arteriovenous graft fistula for, interposition, Jan., 25–28
allogenic vein graft as, preserved, Jan., 27
autogenous vein graft as, Jan., 26–27
bovine carotid heterograft as, Jan., 27–28
devices for needleless dialysis, Jan., 28
materials for, Jan., 26–28
patency rate, Jan., 30
polytetrafluoroethylene, Jan., 28
umbilical vein graft as, human, Jan., 27
complications, Jan., 32–36
conclusions and strategy, Jan., 40–41
history, Jan., 15
hypertension complicating, venous, Jan., 34, 35
indication, Jan., 17–18
infection complicating, Jan., 33
in-use
angiography of, Jan., 37
clinical examination, Jan., 36–37
follow-up, Jan., 36–38
ultrasound of, Jan., 38
results, Jan., 28–31
authors', Jan., 30–31
from literature, Jan., 28–30
salvage
angioplasty for, percutaneous, Jan., 38–39
procedures, Jan., 38–40
surgical revision for, Jan., 39–40
thrombectomy for, Jan., 39–40
thrombolysis for, Jan., 39
steal syndrome complicating, Jan., 34–36
technical aspects, Jan., 18–20
thrombosis complicating, Jan., 32–33
Vascular access for nonuremic patients, long-term, Jan., 7–15
central venous catheter for (*see* Catheter, central venous)
history, Jan., 7–8
indications, Jan., 8
totally implantable systems, Jan., 10–15
for arterial access, Jan., 13–15
for arterial access, Basel experience with, Jan., 15
for hepatic artery perfusion, Jan., 14
Huber needle for, Jan., 13
materials for, Jan., 12
schematic drawing of, Jan., 11
for venous access, Jan., 10–12
for venous access, Basel experience with, Jan., 11
Vasoactive intestinal polypeptide: role in VIPoma, June, 357–359
Vein
access
central, catheter for (*see* Catheter, central venous)
central, for total parenteral nutrition, Jan., 8
implantable system for, Jan., 10–12
implantable system for, Basel experience with, Jan., 11
peripheral, for total parenteral nutrition, Jan., 8
arteriovenous (*see* Arteriovenous)
blood gases, mixed, measurements in sepsis, Aug., 489
hypertension complicating vascular access for hemodialysis, Jan., 34, 35
jugular, puncture for central venous catheterization, Jan., 9
portal (*see* Portal, vein)
pressure, central, in diagnosis of congestive heart failure, Aug., 528–529
subclavian, puncture for central venous catheterization, Jan., 8–9

Vein *(cont.)*
sampling for localization of VIPoma, June, 361
umbilical, graft for hemodialysis, Jan., 27
Vena cava (*see* Transplantation, liver, piggyback technique with preservation of vena cava)
Venoarterial extracorporeal circulation (*see* Extracorporeal life support, venoarterial)
Venovenous extracorporeal circulation (*see* Extracorporeal life support, venovenous)
Ventilation
abnormalities in membrane lungs during extracorporeal life support, Oct., 657
assist control, Aug., 479, 480
conversion to intermittent mandatory, Aug., 485–486
intermittent mandatory, Aug., 479–480
conversion from assist mode to, Aug., 485–486
synchronized, Aug., 486–487
inverse ratio, Aug., 504–507
pressure control, volume, pressure, and flow characteristics for, Aug., 506
mechanical
indications, Aug., 482
weaning from, Aug., 510–516
/perfusion mismatch in membrane lungs during extracorporeal life support, Oct., 657
positive pressure, airway pressure curve for, Aug., 478
pressure control, Aug., 504–507
pressure support
weaning from, Aug., 514
during weaning from mechanical ventilation, Aug., 511–514
spontaneous, airway pressure curve for, Aug., 478
volume control, volume, pressure, and flow characteristics for, Aug., 506
Vessels
(*See also* Vascular)
cardiovascular symptoms in insulinoma, June, 339
facial, anatomic relationships of parotid and submandibular glands to, Dec., 782
kidney, after reperfusion of inadequately preserved kidneys, Feb., 103
Vincristine
in neuroblastoma, Sept., 603
in rectal cancer, May, 282
VIPoma, June, 356–363
anatomy, June, 357
angiogram, June, 362
clinical presentation, June, 359–360
differential diagnosis, June, 361
epidemiology, June, 357
localization, June, 361
pancreatic distribution, June, 358
pathobiology, June, 357–359
surgery in, June, 361–362
treatment, June, 361–363
Virus
hepatitis, in liver transplantation (*see under* Transplantation, liver)
immunodeficiency, human, carrier state, and liver transplantation, Apr., 212–213
Visualization: for lithotripter, Nov., 733–734
VM-26: in neuroblastoma, Sept., 603, 604
Vomiting: after FK 506 in liver transplantation (in dog), Mar., 144
Volvovaginitis: in glucagonoma, June, *Color Plate* at 344; 351

W

Waddell-Calne biliary reconstruction after liver transplantation, Feb., 90
typical complication with, Feb., 91
Warthin's tumor, Dec., 794–795
CT of, Dec., 816

Weaning
from extracorporeal life support, Oct., 664–665
from mechanical ventilation, Aug., 510–516
from pressure support, Aug., 514
Weight
loss in glucagonoma, June, 351
nomogram relating height and weight to body surface area, Aug., 498
White cells: effect of extracorporeal life support on, Oct., 649
Wind sprints: in weaning from mechanical ventilation, Aug., 514
Work of breathing: effect of endotracheal tube size on, Aug., 513

X

X-rays (*see* Radiography)

Y

York Mason's transsphincteric approach: for excision of rectal cancer, May, 270

Z

Zantac: in Zollinger-Ellison syndrome, June, 331
Zollinger-Ellison syndrome, June, 317–335
anatomy, June, 318–319
angiography in, June, 326–327
clinical presentation, June, 320–321
CT in, June, 325
diagnosis, June, 321–330
epidemiology, June, 317–318
histology, June, 318–319
localization, June, 324–330
pathobiology, June, 319–320
portal venous sampling in, percutaneous transhepatic, June, 328, 329
surgery in, June, 333–335
treatment, June, 330–335
Zoster: varicella-zoster hepatitis after liver transplantation, Apr., 190–191



STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION

1A. Title of Publication: Current Problems in Surgery	1B. Publication No.: 0 0 1 1 3 9 4 0
2. Frequency of Issue: Monthly	3. Filing Date: 10/1/90
3A. No. of Issues Published Annually: 12	3B. Annual Subscription Price: $75.00

4. Complete Mailing Address of Known Office of Publication (Not Printer): Year Book, Inc., 200 North LaSalle Street, Chicago, IL 60601

5. Complete Mailing Address of the Headquarters or General Business Offices of the Publisher: Year Book, Inc., 11830 Westline Industrial Drive, St. Louis, MO 63146

6. Full Names and Complete Mailing Address of Publisher, Editor, and Managing Editor: Publisher: Year Book, Inc., 345 Grant Road, Littleton, MA 01460

Editor: n/a

Managing Editor: Richard Wallace, Year Book, Inc., 345 Grant Road, Littleton, MA 01460

7. Owner: If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated. (Item must be completed.)

Full Name	Complete Mailing Address
Year Book, Inc.	11830 Westline Industrial Drive St. Louis, MO 63146

8. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages or Other Securities: If none, so state: None

Full Name	Complete Mailing Address
None	

9. For Completion by Nonprofit Organizations Authorized To Mail at Special Rates (DMM Section 424.12 only): The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes: Have not changed during Preceding 12 Months / Have changed during Preceding 12 Months (If changed, publisher must submit explanation of change with this statement.)

10. Extent and Nature of Circulation (See instructions on reverse side)	Average No. Copies Each Issue During Preceding 12 Months	Actual No. Copies of Single Issue Published Nearest to Filing Date
A. Total No. Copies (Net Press Run)	9780	8800
B. Paid and/or Requested Circulation 1. Sales through dealers and carriers, street vendors and counter sales	1732	1225
2. Mail Subscription (Paid and/or requested)	7912	7667
C. Total Paid and/or Requested Circulation (Sum of 10B1 and 10B2)	9644	7192
D. Free Distribution by Mail, Carrier or Other Means Samples, Complimentary, and Other Free Copies	58	38
E. Total Distribution (Sum of C and D)	9202	7230
F. Copies Not Distributed 1. Office use, left over, unaccounted, spoiled after printing	498	730
2. Return from News Agents	-0-	-0-
G. TOTAL (Sum of E, F1 and 2—should equal net press run shown in A)	9780	8800

11. I certify that the statements made by me above are correct and complete. Signature and Title of Editor, Publisher, Business Manager, or Owner: Richard J. Wallace, Managing Editor